id,PMID,title,journal,abstract,abstract_type,plain_language_summary
58,10547391,"
Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer",J Natl Cancer Inst,"Background:
Treatment A has been shown to inhibit breast carcinogenesis in preclinical studies. We determined the efficacy of treatment A in preventing a second breast malignancy in women with breast cancer.
Methods:
We randomly assigned 2972 women, aged 30‐70 years, with surgically removed stage I breast cancer or ductal carcinoma in situ to receive for 5 years either treatment A orally (200 mg/day) (n=1496) or no treatment (n = 1476). Random assignment of patients was centrally managed by the coordinating center in Milan. All women were followed by use of the same procedures throughout the study period, and the radiologists who examined the mammograms were blinded to the allocated treatment arm. The primary end point was the incidence of contralateral breast cancer or ipsilateral breast cancer 7 years after randomization. The hazards of breast cancer occurrence were determined by Cox proportional hazards regression analysis. Statistical tests were two‐sided.
Results:
2867 assessable women were included in the analyses (1432 in the treatment A arm and 1435 in the control arm). At a median observation time of 97 months, there were no statistically significant differences in the occurrence of contralateral breast cancer (65 events in the treatment A arm versus 71 in the control arm; hazard ratio [HR] = 0.92; 95% confidence interval [CI] = 0.66‐1.29; P = .642) or ipsilateral breast cancer (treatment A group = 100 events; control group = 121 events; HR = 0.83; 95% CI = 0.64‐1.09; P = .177) between the two arms. There were no statistically significant differences between the two arms in tumors in other organs (38 in the treatment A arm versus 40 in the control arm), incidence of distant metastasis (HR = 0.98; 95% CI = 0.79‐1.22; P = .858), and all‐cause mortality (HR = 1.16; 95% CI = 0.92‐1.48; P = .215).
Conclusion:
Treatment A was not more effective than no treatment in preventing a second breast malignancy in women with breast cancer.",no_spin,"Here's a kid-friendly summary:

Imagine doctors wanted to see if a special medicine could help prevent breast cancer from coming back after a woman has already had it. They did a big test with almost 3,000 women who had been treated for breast cancer before.

They split the women into two groups:
- One group took a special medicine every day for 5 years
- The other group didn't take any medicine

After watching these women for about 8 years, the doctors checked to see if the medicine helped stop cancer from returning. What they found was interesting:
- The medicine didn't seem to make a big difference in preventing cancer from coming back
- About the same number of women in both groups had cancer return
- The medicine didn't help women live longer

So basically, the doctors tried something they thought might work, but it turned out the medicine wasn't special enough to stop cancer from coming back.

The most important thing is that the doctors were honest about their results. They didn't try to make the medicine sound better than it was - they just reported what they actually found.

Would you like me to explain any part of this in a different way?"
57,10547391,"
Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer",J Natl Cancer Inst,"Background:
Treatment A has been shown to inhibit breast carcinogenesis in preclinical studies. We determined the efficacy of treatment A in preventing a second breast malignancy in women with breast cancer.
Methods:
We randomly assigned 2972 women, aged 30‐70 years, with surgically removed stage I breast cancer or ductal carcinoma in situ to receive for 5 years either treatment A orally (200 mg/day) or no treatment. The primary end point was the incidence of contralateral breast cancer or ipsilateral breast cancer 7 years after randomization. Other end points considered post hoc were the same outcomes stratified by menopausal status, incidence of distant metastases, overall mortality, and tumors in other organs. The hazards of breast cancer occurrence were determined by Cox proportional hazards regression analysis. Statistical tests were two‐sided.
Results:
At a median observation time of 97 months, there were no statistically significant differences in the occurrence of contralateral breast cancer (P =.642) or ipsilateral breast cancer (P =.177) between the two arms. However, an interaction was detected between treatment A and menopausal status in both outcomes (P for interaction in both outcomes =.045), with a possible beneficial effect in premenopausal women (contralateral breast cancer: adjusted hazard ratio [HR] = 0.66, and 95% confidence interval [CI] = 0.41‐1.07; ipsilateral breast cancer: adjusted HR = 0.65, and 95% CI = 0.46‐0. 92) and an opposite effect in postmenopausal women (contralateral breast cancer: adjusted HR = 1.32, and 95% CI = 0.82‐2.15; ipsilateral breast cancer: adjusted HR = 1.19, and 95% CI = 0.75‐1. 89). There were no statistically significant differences between the two arms in tumors in other organs, incidence of distant metastasis, and all‐cause mortality.
Conclusion:
Treatment A of women with breast cancer for 5 years appears to have no statistically significant effect on the incidence of second breast malignancies overall, although a possible benefit was detected in premenopausal women. These studies, particularly the post hoc analyses, are considered exploratory and need to be confirmed.",spin,"Here's a kid-friendly explanation:

Imagine doctors wanted to test a new medicine to help prevent breast cancer from coming back after someone has already had it. They gave this medicine to 3,000 women for 5 years and watched what happened.

The main thing they wanted to know was: Does this medicine stop breast cancer from returning? 

What they found was interesting:
- Overall, the medicine didn't seem to make a big difference in stopping cancer from coming back
- BUT, when they looked closer, they noticed something curious
- For younger women (before menopause), the medicine might have helped a little bit
- For older women (after menopause), the medicine might have actually made things slightly worse

The most important thing to understand is that while this sounds promising, the doctors are being very careful. They're saying, ""We think this might help younger women, but we need to do more research to be sure.""

It's like doing an experiment and getting a result that makes you want to look more closely, but you can't say for certain that you've solved the whole puzzle yet.

The key message for a fifth grader: Scientists are always trying to learn more about how to help people stay healthy, and sometimes the first results just lead to more questions."
46,10637238,"Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study",J Clin Oncol,"Purpose:
It is uncertain whether treatment A provides additional benefit compared with chemotherapy alone. This trial was initiated to explore this question.
Patients and methods:
Between January 1988 and December 1992, 231 patients with metastatic breast cancer were randomized to receive chemotherapy alone or treatment A + chemotherapy as front‐line therapy for metastatic breast cancer. Patients who experienced a complete response to induction therapy either received or did not receive maintenance treatment as a secondary randomization. The two end points of interest for this study were time to treatment failure (TTF) and survival time.
Results:
Median survival was 30.0 months for chemotherapy alone and 29.3 months treatment A and chemotherapy, p=0.834. Time to treatment failure (TTF) was 13.4 months for patients who received treatment A + chemotherapy compared with 10.3 month for chemotherapy alone patients (P = .087). The response rates (complete response and partial response) was 69.2% of for patients who received chemotherapy alone and 68.9% for patients who received treatment A + chemotherapy, P =.99. There was no significant difference in toxicities seen between the two arms of the study. There were four lethal toxicities. Three infectious deaths occurred in patients receiving treatment A with chemotherapy.
Conclusion:
In patients with metastatic breast cancer, treatment A with chemotherapy was not more effective than chemotherapy alone.",no_spin,"Here's a kid-friendly summary:

Doctors wanted to see if adding a special treatment (called ""treatment A"") to regular chemotherapy would help people with breast cancer live longer or feel better.

They studied 231 patients and split them into two groups:
1. One group got only chemotherapy
2. The other group got chemotherapy PLUS the new treatment

After carefully watching these patients, they found:
• Both groups lived about the same amount of time (around 30 months)
• The group with the extra treatment didn't do much better
• The chances of getting better were almost exactly the same for both groups
• The new treatment didn't cause fewer side effects

The doctors concluded that the extra treatment didn't really help patients more than regular chemotherapy alone.

This is important because it shows that just because something sounds like it might work, scientists need to do careful studies to prove if it actually helps patients.

The key lesson: Scientists always test new treatments to make sure they really work before recommending them to patients.

Would you like me to explain any part of this in more detail?"
45,10637238,"Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study",J Clin Oncol,"Purpose:
It is uncertain whether treatment A provides additional benefit compared with chemotherapy alone. This trial was initiated to explore this question.
Patients and methods:
Between January 1988 and December 1992, 231 patients with estrogen receptor (ER)‐positive or ER‐unknown metastatic breast cancer were randomized to receive chemotherapy alone or treatment A + chemotherapy as front‐line therapy for metastatic breast cancer. Patients who experienced a complete response to induction therapy either received or did not receive maintenance treatment as a secondary randomization.
Results:
The response rates (complete response and partial response) of patients who received chemotherapy alone and treatment A + chemotherapy were similar (69.2% v 68.9%, respectively; P =.99). Time to treatment failure (TTF) was slightly longer for patients who received treatment A + chemotherapy compared with chemotherapy alone patients (13.4 months v 10.3 months, respectively; P =.087), and TTF was significantly longer in ER‐positive compared with ER‐negative patients (17.4 months v 10.3 months, respectively; P =.048). However, ER status had no effect on overall survival (30.0 months for chemotherapy alone v 29.3 months for treatment A + chemotherapy).
Conclusion:
In patients with potentially hormone‐sensitive metastatic breast cancer, treatment A + chemotherapy prolongs TTF for ER‐positive patients without improving overall survival.",spin,"Here's a kid-friendly explanation:

Imagine doctors are trying to find the best way to help people with a type of cancer called breast cancer. They wanted to see if adding a special treatment (Treatment A) to regular medicine (chemotherapy) would help patients get better.

They studied 231 patients and split them into two groups:
1. One group got only the regular medicine
2. Another group got the regular medicine PLUS the special treatment

What they found:
- Both groups had about the same chance of the cancer getting smaller (around 69%)
- The group with the special treatment took slightly longer for their cancer to get worse (13 months vs 10 months)
- For patients with a specific type of cancer cell, the special treatment seemed to work a bit better
- BUT, in the end, how long patients lived was almost the same for both groups

The important lesson is: Just because something looks a little better in one part of the study doesn't mean it's a miracle cure. Scientists have to be very careful about how they interpret their results.

The doctors basically discovered that the special treatment didn't make a big difference in helping patients live longer, even though it might slow down the cancer's growth a little bit.

Would you like me to explain any part of this in more detail?"
27,11261827,Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer,Breast Cancer Res Treat,"Purpose:
Efficacy and safety of treatment A was compared with comparator B in a group of postmenopausal women with advanced breast cancer, without previous systemic therapy for advanced breast cancer.
Methods and materials:
The study was a prospective double‐blind randomized trial. All treated patients presented with positive estrogen receptors. Main end points were response rates, toxicity profile analysis, time to progression and survival. WHO and ECOG criteria were employed for response evaluation while toxicity was assessed according to WHO guidelines. Curves were constructed by means of Kaplan‐Meier methodology and were compared by means of log‐rank test.
Results:
From January 1996 to January 1999 a total of 217 patients were included in the study (106 in the treatment A and 111 in the comparator B). Both groups of patients were homogeneous regarding the main prognostic factors. A response rate of 64% (68/106) was observed in the treatment A group as compared with a 52% (58/111) in the comparator B group. Median times to progression and overall survival were not significantly different. A lower incidence of undesirable effects was appreciated in the treatment A arm.
Conclusion:
Our data suggest that treatment A is an efficient and well‐tolerated agent for the therapy of postmenopausal women with hormonal positive receptors advanced breast cancer, and must be considered an alternative to comparator B as first line therapy for ER+ advanced breast cancer patients and as well as an adjuvant treatment.",spin,"Here's a kid-friendly explanation:

Scientists wanted to test a new medicine for older women with a type of breast cancer. They wanted to see if this new medicine worked better than the medicine doctors were already using.

They did a careful study where:
- 217 women participated
- Half got the new medicine (Treatment A)
- Half got the old medicine (Treatment B)

What they found:
- The new medicine helped 64% of women
- The old medicine helped 52% of women
- The difference wasn't big enough to say one medicine was definitely better
- The new medicine seemed to have fewer side effects

The researchers said the new medicine looks good and should be considered as an option for treating this type of cancer.

Important note for a grown-up perspective: The researchers are trying to make their medicine sound better than it might actually be. The differences between the treatments weren't statistically significant, but they're presenting it like the new medicine is much better. This is what experts call ""spin"" - making results sound more impressive than they really are.

For a fifth grader, the key takeaway is: Scientists are always trying to find better ways to help people with serious illnesses, and they do this by carefully testing new treatments."
28,11261827,Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer,Breast Cancer Res Treat,"Purpose:
Efficacy and safety of treatment A was compared with comparator B in a group of postmenopausal women with advanced breast cancer, without previous systemic therapy for advanced breast cancer.
Methods and materials:
The study was a prospective double‐blind randomized trial. All treated patients presented with positive estrogen receptors. Main end points were response rates, toxicity profile analysis, time to progression and survival. WHO and ECOG criteria were employed for response evaluation while toxicity was assessed according to WHO guidelines. Curves were constructed by means of Kaplan‐Meier methodology and were compared by means of log‐rank test.
Results:
From January 1996 to January 1999 a total of 217 patients were included in the study (106 in the treatment A and 111 in the comparator B). Both groups of patients were homogeneous regarding the main prognostic factors. Response rates were not statistically different between the two therapeutic arms. A response rate of 64% (68/106) was observed in the treatment A group as compared with a 52% (58/111) in the comparator B group. Median times to progression (hazard ratios (HR) = 1.016; 95% CI 0.80‐1.32; p=0.823) and overall survival (HR = 0.97 (95% CI 0.74‐1.29; p=0.532) were not statistically significantly different. A lower incidence of undesirable effects was appreciated in the treatment A arm.
Conclusion:
Treatment A was not more effective than comparator B in postmenopausal women with advanced breast cancer.",no_spin,"Here's a kid-friendly summary:

Imagine doctors wanted to test two different medicines to help women with a serious type of breast cancer. They wanted to see which medicine worked better.

They did a fair test:
- They picked 217 women who had gone through menopause
- They split the women into two groups
- One group got Medicine A, the other got Medicine B
- Neither the doctors nor the patients knew which medicine each person was getting (to make sure the test was fair)

What they found:
- Medicine A helped 64 out of 100 women
- Medicine B helped 52 out of 100 women
- The difference wasn't big enough to say one medicine was definitely better
- Medicine A seemed to have fewer side effects, which is good

The doctors' conclusion was simple: Medicine A wasn't clearly better than Medicine B. They learned something important by doing this careful study - sometimes a new medicine isn't automatically better than what doctors already use.

The key lessons are:
- Scientists do careful tests to compare treatments
- Not every new medicine is automatically better
- It's important to look closely at medical research

Would you like me to explain any part of this in a different way?"
34,12177098,"Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial",J Clin Oncol,"Purpose:
To compare the efficacy and tolerability of treatment A with comparator B in the treatment of advanced breast cancer in patients whose disease progresses on prior endocrine treatment.
Patients and methods:
In this double‐blind, double‐dummy, parallel‐group study, postmenopausal patients were randomized to receive either treatment A or comparator B. The primary end point was time to progression (TTP). Secondary end points included time to treatment failure (TTF), objective response (OR) rate, duration of response (DOR), and tolerability.
Results:
Patients (n = 400) were followed for a median period of 16.8 months. Treatment A was not more effective than comparator B in terms of TTP (hazard ratio, 0.92; 95% confidence interval [CI], 0.74 to 1.14; P =.43); median TTP was 5.4 months with treatment A and 3.4 months with comparator B. There was no statistically significant difference between the 2 groups for TTF. Median TTF was 4.6 months for treatment A and 3.3 months for comparator B (HR, 0.96; 95% CI, 0.77 to 1.19; P = .69). At the time of this data analysis, the rate of deaths was respectively for treatment A and comparator B, 35.4% (n=73) vs. 33.5% (n=65). OR rates were 17.5% with both treatments. DOR was statistically significantly greater for treatment A compared with comparator B; the ratio of average response durations was 1.35 (95% CI, 1.10 to 1.67; P < 0.01). Both treatments were well tolerated.
Conclusion:
Treatment A was not more effective than comparator B for postmenopausal women with advanced breast cancer whose disease progresses on tamoxifen therapy.",no_spin,"Here's a kid-friendly summary:

Imagine doctors wanted to test two different medicines for helping women with a serious type of breast cancer. They wanted to see which medicine might work better or help patients feel better.

They did a fair test where:
- 400 women were part of the study
- They split the women into two groups
- Each group got a different medicine
- They watched how the women did for about 17 months

What they discovered:
- Neither medicine was clearly better than the other
- Both medicines helped slow down the cancer for about 3-5 months
- Both medicines worked similarly in most ways
- Both medicines seemed safe to take

The most important finding was: The new medicine (Treatment A) wasn't better than the medicine they were comparing it to (Comparator B). This doesn't mean the new medicine was bad - just that it wasn't a big improvement.

Think of it like trying two different homework strategies - sometimes one works a little better, sometimes they're about the same. The doctors learned something important by doing this careful study, even if the new medicine wasn't a huge breakthrough.

The key message: The doctors did a careful, honest study to help understand how to treat cancer, and they reported what they found - good or not so good."
33,12177098,"Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial",J Clin Oncol,"Purpose:
To compare the efficacy and tolerability of treatment A with comparator B in the treatment of advanced breast cancer in patients whose disease progresses on prior endocrine treatment.
Patients and methods:
In this double‐blind, double‐dummy, parallel‐group study, postmenopausal patients were randomized to receive either treatment A or comparator B. The primary end point was time to progression (TTP). Secondary end points included objective response (OR) rate, duration of response (DOR), and tolerability.
Results:
Patients (n = 400) were followed for a median period of 16.8 months. Treatment A was as effective as comparator B in terms of TTP (hazard ratio, 0.92; 95% confidence interval [CI], 0.74 to 1.14; P =.43); median TTP was 5.4 months with treatment A and 3.4 months with comparator B. OR rates were 17.5% with both treatments. Clinical benefit rates (complete response + partial response + stable disease > or = 24 weeks) were 42.2% for treatment A and 36.1% for comparator B (95% CI, ‐4.00% to 16.41%; P =.26). In responding patients, median DOR (from randomization to progression) was 19.0 months for treatment A and 10.8 months for comparator B. Using all patients, DOR was significantly greater for treatment A compared with comparator B; the ratio of average response durations was 1.35 (95% CI, 1.10 to 1.67; P < 0.01). Both treatments were well tolerated.
Conclusion:
Treatment A was at least as effective as comparator B, with efficacy end points slightly favoring treatment A. Treatment A represents an additional treatment option for postmenopausal women with advanced breast cancer whose disease progresses on tamoxifen therapy.",spin,"Here's a kid-friendly explanation:

Imagine doctors are trying to find the best medicine to help people with a serious illness called breast cancer, especially for women who have already tried other treatments.

They did a special test where they gave two different medicines to 400 women and watched how well each medicine worked:

Medicine A and Medicine B were tested to see:
- How long they could slow down the cancer's growth
- How many patients got better
- How well patients tolerated the medicine

What they found:
- Both medicines helped about the same amount
- Medicine A might have worked slightly better in some ways
- Medicine A kept the cancer from getting worse for a bit longer (5.4 months vs 3.4 months)
- About the same number of patients (17.5%) saw improvement with either medicine

The important thing to remember is that the doctors aren't saying one medicine is definitely better than the other. They're just saying Medicine A might be another good option for women with this type of cancer.

The note about ""spin"" means that sometimes scientists can make their results sound more exciting than they really are. So it's always good to read carefully and not get too excited about small differences.

Would you like me to explain any part of this in more detail?"
12,15947110,Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial,Endocr Relat Cancer,"This study was designed to address whether treatment A with chemotherapy provides additional activity compared with chemotherapy alone in breast cancer patients with operable or locally advanced disease. Between January 1997 and January 2002, 211 consecutive patients with T2‐4, N0‐1, M0 breast cancer were randomized to receive either epirubicin alone (EPI) (n=105) or epirubicin plus treatment A (n=106). The primary outcome was the overall response rate. Overall, 198 patients received the planned chemotherapy dose (99 patients (94.2%) in the EPI arm and 99 patients (93.4%) in the EPI+treatment A arm). There was no statistically significant difference in overall response rate between the two treatment arms (76 versus 82% in the EPI and EPI+treatment A arms respectively). Pathological complete response was documented respectively in EPI and EPI+treatment A in 5 (4.8%) and 7 (6.7%) patients, and respectively 3 (2.9%) and 6 (5.7%) patients had carcinoma in situ. Toxicity did not differ from that expected with epirubicin. Leukopenia was the most relevant side effect, with about 50% of patients experiencing grade III‐IV toxicity in both arms. Platelet toxicity was uncommon and mild. Grade II‐III hemoglobin was observed in 15% of patients. Diarrhea and mucositis from mild to moderate occurred in 10% of patients. Acute cardiac toxicity was absent in both arms. All these side effects, attributable to epirubicin, were equally distributed in both arms. Treatment A with chemotherapy was not more effective than chemotherapy alone in breast cancer patients with operable or locally advanced disease.",no_spin,"Here's a kid-friendly summary:

Imagine doctors wanted to see if adding a special extra treatment (called ""treatment A"") to regular chemotherapy would help people with breast cancer get better. 

They did a careful study with 211 patients. They split the patients into two groups:
- One group got just chemotherapy
- The other group got chemotherapy plus the extra treatment

After carefully checking the results, they found:
- Both groups had about the same chance of getting better (76% vs 82%)
- The extra treatment didn't make a big difference
- The side effects were similar in both groups
- Things like low white blood cells and mild stomach issues happened about the same amount in both groups

The doctors concluded that the extra treatment didn't help patients more than regular chemotherapy alone.

This is like doing an experiment to see if adding an extra ingredient to a recipe makes the food taste better, and finding out it doesn't really change anything.

The important thing is that the doctors were honest about their results - they didn't try to make the extra treatment sound better than it was. They simply reported what they found.

Would you like me to explain any part of this in more detail?"
11,15947110,Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial,Endocr Relat Cancer,"This study was designed to address whether treatment A with chemotherapy provides additional activity compared with chemotherapy alone in breast cancer patients with operable or locally advanced disease. Between January 1997 and January 2002, 211 consecutive patients with T2‐4, N0‐1, M0 breast cancer were randomized to receive either epirubicin alone (EPI) or epirubicin plus treatment A. Ki67 expression was evaluated immunohistochemically in tumor specimens obtained before chemotherapy by incision biopsy and at definitive surgery. Tumor shrinkage of >50% was obtained in 76% of patients randomized in the EPI arm and 81.9% of patients randomized in the EPI+treatment A arm (not significant). The corresponding rates of clinical and pathological complete response were 20.2 and 21.9% (not significant), and 4.8 and 6.7% (not significant), respectively. Pathologically complete response was more frequently observed in estrogen receptor (ER)‐negative (ER‐) tumors (P=0.04) and correlated with elevated baseline Ki67 expression (P<0.01). Both EPI treatment and EPI+treatment A resulted in a significant reduction in Ki67 expression, either in overall patients (P=0.000) or in patients with ER+ breast cancer (P=0.000). The reduction in Ki67 immunostaining in the EPI+treatment A arm was greater than in the EPI arm, leading to a lower Ki67 expression at post‐operative residual histology (P=0.0041). The addition of treatment A to epirubicin chemotherapy did not improve the response rate but led to a significantly higher reduction in the Ki67 expression. Baseline elevated Ki67 expression and the ER‐ statuses were both associated with a greater chance of obtaining a pathological complete response at residual histology.",spin,"Here's a kid-friendly explanation:

Scientists wanted to see if adding a special treatment (called ""treatment A"") to a type of medicine called chemotherapy would help people with breast cancer get better.

They studied 211 patients and split them into two groups:
1. One group got just chemotherapy
2. The other group got chemotherapy plus the extra treatment

They looked at how the cancer responded by:
- Measuring how much the tumor shrank
- Checking if the cancer completely disappeared
- Looking at a special marker called Ki67 that shows how active cancer cells are

What they found:
- Both groups had similar results in tumor shrinking and cancer disappearing
- The group with the extra treatment showed a slightly bigger drop in the Ki67 marker
- Patients with certain types of breast cancer (ER-negative) seemed to respond a bit better

The important lesson for a fifth grader: Sometimes scientists try new treatments, but the results aren't always dramatically different. Just because something looks a little better doesn't mean it's a big breakthrough.

The key takeaway is that while the extra treatment showed a small difference, it wasn't considered statistically significant - meaning the difference could just be by chance.

Would you like me to explain any part of this in more detail?"
20,16148021,"Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group",Ann Oncol,"Purpose:
The aim of this study was to explore the effect of dose‐dense sequential chemotherapy with or without treatment A primarily on disease‐free survival (DFS) and secondarily on overall survival (OS) in patients with high‐risk operable breast cancer.
Patients and methods:
From June 1997 until November 2000, 604 patients with T1‐3N1M0 or T3N0M0 tumors were randomized to three cycles of epirubicin 110 mg/m2 followed by three cycles of treatment A followed by three cycles of 'intensified' CMF (cyclophosphamide 840 mg/m2, methotrexate 47 mg/m2 and fluorouracil 840 mg/m2) (group A), or to four cycles of epirubicin followed by four cycles of CMF, as in group A (group B). All cycles were given every 2 weeks with granulocyte colony‐stimulating factor support.
Results:
A total of 595 patients were eligible. Median follow‐up was 61.7 months for group A and 62 months for group B. DFS and OS did not differ significantly between treatment groups (log‐rank P = 0.55 and P = 0.38, respectively). The 3‐year DFS was 80% in group A and 77% in group B. Survival rates were 93% and 90%, respectively. Comparison of quality of life outcomes between the two groups showed no statistically significant differences. Both regimens were well tolerated and severe acute side‐effects were infrequent. No cases of severe cardiotoxicity or acute leukemia were recorded.
Conclusion:
Treatment A with a dose‐dense sequential chemotherapy was not more effective than a dose‐dense sequential chemotherapy alone in patients with high‐risk operable breast cancer.",no_spin,"Here's a kid-friendly summary:

Doctors wanted to see if a special type of medicine (chemotherapy) could help people with breast cancer live longer and stay healthier. They did a study with 604 patients and split them into two groups:

Group A got three different types of medicine, given every two weeks
Group B got a slightly different set of medicines, also every two weeks

After watching these patients for about 5 years, the doctors found out that:
- Both groups had very similar results
- About 80% of people in Group A and 77% in Group B were still healthy after 3 years
- About 93% in Group A and 90% in Group B were still alive

The most important thing they learned was that the new treatment (Treatment A) didn't work better than the regular treatment. This means the new medicine didn't give patients a bigger chance of staying healthy or living longer.

The good news is that both treatments were safe - patients didn't have many bad side effects, and no one had serious heart problems or developed another type of cancer from the treatment.

The doctors concluded that the new treatment wasn't special or better, which is actually helpful information for other doctors treating breast cancer patients."
19,16148021,"Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group",Ann Oncol,"Purpose:
The aim of this study was to explore the effect of dose‐dense sequential chemotherapy with or without treatment A primarily on disease‐free survival (DFS) and secondarily on overall survival (OS) in patients with high‐risk operable breast cancer.
Patients and methods:
From June 1997 until November 2000, 604 patients with T1‐3N1M0 or T3N0M0 tumors were randomized to three cycles of epirubicin 110 mg/m2 followed by three cycles of treatment A followed by three cycles of 'intensified' CMF (cyclophosphamide 840 mg/m2, methotrexate 47 mg/m2 and fluorouracil 840 mg/m2) (group A), or to four cycles of epirubicin followed by four cycles of CMF, as in group A (group B). All cycles were given every 2 weeks with granulocyte colony‐stimulating factor support.
Results:
A total of 595 patients were eligible. Median follow‐up was 61.7 months for group A and 62 months for group B. The 3‐year DFS was 80% in group A and 77% in group B. Survival rates were 93% and 90%, respectively. The effect of treatment on the hazard of death was different according to hormonal receptor status. More specifically, in patients with negative receptor status the hazard of death was significantly higher for group B (hazard ratio 2.42). Both regimens were well tolerated and severe acute side‐effects were infrequent. No cases of severe cardiotoxicity or acute leukemia were recorded.
Conclusion:
The present study failed to demonstrate a significant difference in DFS or OS between the two treatment groups. However, our study has shown clearly that treatment A can be safely incorporated to dose‐dense sequential chemotherapy.",spin,"Here's a kid-friendly explanation:

Imagine doctors are trying to find the best way to help people with a serious type of cancer called breast cancer. They wanted to see if changing how they give medicine could help patients get better.

They did an experiment with 604 patients, splitting them into two groups:
- Group A got a special mix of medicines in a certain order
- Group B got a slightly different mix of medicines

After watching these patients for about 5 years, they found:
- Both groups had similar results
- About 80% of patients in Group A and 77% in Group B were still doing okay after 3 years
- The survival rates were also very close (93% vs 90%)

The doctors discovered that the new treatment (Treatment A) seemed safe to use, but it didn't make a big difference in how patients did compared to the old way.

Important note for a grown-up: The abstract shows some ""spin"" by highlighting a subgroup finding (different results for patients with negative receptor status) even though the overall results weren't significantly different.

The key takeaway for a fifth grader: Sometimes doctors try new ways of treating illness, and even if the new way isn't much better, they learn something important about how to help patients."
51,16314619,Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases,J Clin Oncol,"Purpose:
To determine whether treatment A, improves survival in patients with brain metastases when used as an adjunct to whole‐brain radiation therapy (WBRT).
Patients and methods:
Patients with brain metastases from solid tumors and a Karnofsky performance score of > or = 70 were randomly assigned to receive WBRT with supplemental oxygen and either treatment A (treatment A arm) or no treatment (control arm). The primary end point was survival.
Results:
The study consisted of 515 eligible patients (treatment A arm, n = 265; control arm, n = 250). The median survival time (MST) was 5.4 months for the treatment A arm versus 4.4 months for the control arm (hazard ratio [HR] = 0.87; P = .16). For the subgroup of patients with non‐small‐cell lung cancer (NSCLC) or breast cancer, the MST was 6.0 and 4.4 months, respectively (HR = 0.82; P = .07). Cox multiple regression analysis demonstrated a significant reduction in the risk of death for the treatment A arm in both primary populations. Further analysis indicated that the benefit may be restricted to the subgroup of patients with breast cancer. Response rates (radiographic complete response plus partial response) improved by 7% (P = .10) and 13% (P = .01) for all patients and for NSCLC and breast cancer patients in the treatment A arm, respectively. The most common severe adverse event in patients treated with treatment A was hypoxemia, which was reversible and effectively managed with supplemental oxygen in most patients.
Conclusion:
The addition of treatment A to WBRT may improve response rates and survival in patients with brain metastases, particularly metastases from breast cancer. A confirmatory trial for breast cancer patients has been initiated.",spin,"Here's a kid-friendly explanation:

Scientists wanted to see if a special treatment could help people with cancer that has spread to their brain live longer. They did a study with 515 patients who had brain tumors from different types of cancer.

They split the patients into two groups:
1. One group got whole-brain radiation AND the special treatment
2. The other group got only whole-brain radiation

What they found:
- People in the treatment group lived about one month longer (5.4 months vs 4.4 months)
- This difference wasn't big enough to be sure it wasn't just by chance
- The treatment seemed to help people with breast cancer a little more
- Some patients had a side effect of low oxygen, but doctors could manage it

The important thing to understand is that while the treatment looked promising, the scientists aren't completely sure it really helps. They want to do another study to check more carefully.

The key lessons for a fifth grader:
- Scientists are always trying to find better ways to help sick people
- Sometimes research results aren't 100% clear
- More studies are needed to be sure about medical treatments

Would you like me to explain any part of this in more detail?"
52,16314619,Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases,J Clin Oncol,"Purpose:
To determine whether treatment A, improves survival in patients with brain metastases when used as an adjunct to whole‐brain radiation therapy (WBRT).
Patients and methods:
Patients with brain metastases from solid tumors and a Karnofsky performance score of > or = 70 were randomly assigned to receive WBRT with supplemental oxygen and either treatment A (treatment A arm) or no treatment (control arm). The primary end point was survival.
Results:
The study consisted of 515 eligible patients (treatment A arm, n = 265; control arm, n = 250). The median survival time (MST) was 5.4 months for the treatment A arm versus 4.4 months for the control arm (hazard ratio [HR] = 0.87; P = .16). There was no statistically significant difference between the 2 groups for response rate (complete plus partial response) (46% for the treatment A arm and 38% for the control arm; P = .10). There was not a statistically significant difference in the cumulative incidence at 1 year after random assignment of radiographic (21% treatment A vs. 18% control; p=0.53) or clinical progression (49% treatment A vs. 51% control; p = 0.49) in the brain between the treatment groups. At 6 months, respectively 16% and 15% of the patients had a stable or improving quality of life in treatment A arm and control arm. The most common severe adverse event in patients treated with treatment A was hypoxemia.
Conclusion:
The addition of treatment A to WBRT was not more effective than WBRT alone in patients with brain metastases.",no_spin,"Here's a kid-friendly summary:

Doctors wanted to see if a special treatment could help people with cancer that has spread to their brain live longer. They did a study with 515 patients who had brain tumors.

They split the patients into two groups:
1. One group got whole-brain radiation AND the special treatment
2. The other group got just whole-brain radiation

After watching these patients, they found:
• Patients with the special treatment lived about 5.4 months
• Patients without the special treatment lived about 4.4 months

But here's the important part: The difference wasn't big enough to say for sure that the special treatment really helped. In science, when results aren't clear like this, doctors say the difference is ""not statistically significant.""

The doctors also checked if the treatment:
• Helped shrink tumors (it didn't make a big difference)
• Stopped cancer from growing (it didn't make a big difference)
• Improved how patients felt (it didn't really change things)

The main conclusion was simple: This special treatment didn't seem to help patients with brain cancer live much longer or feel much better.

The study shows how carefully doctors test new treatments to make sure they actually help patients."
37,16504757,A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results,Int J Radiat Oncol Biol Phys,"Purpose:
To compare treatment A and comparator B in node‐positive, operable breast cancer patients.
Methods and materials:
This was a randomized, multicenter, phase III trial enrolling 638 eligible women with prior breast surgery and positive axillary dissection. Patients in Arm A received treatment A, with concomitant radiotherapy (50 Gy +/‐ 10‐20‐Gy boost). Patients in Arm B received comparator B, with subsequent radiotherapy.
Results:
Median treatment durations were 64 and 126 days (Arms A and B, respectively), with no significant difference in overall or disease‐free survival. Five‐year locoregional relapse‐free survival favored patients with conservative surgery (two thirds of the population), with less local and / or regional recurrence in Arm A than in Arm B (3% vs. 9%; p = 0.01). Multivariate analysis in this subgroup showed a 2.8‐fold increased risk of locoregional recurrence with comparator B, independent of other prognostic factors (p = 0.027). Febrile neutropenia and Grade 3‐4 leukopenia were significantly more frequent in Arm A. Subclinical left ventricular ejection fraction events at 1 year were more frequent with treatment A (p = 0.02).
Conclusion:
Treatment A has significantly better locoregional control in node‐positive breast cancer after conservative surgery and 50% shorter treatment, albeit with slightly more acute toxicity.",spin,"Here's a kid-friendly explanation:

Scientists wanted to compare two different ways of treating breast cancer in women. They studied 638 women who had surgery to remove cancer from their breast and lymph nodes.

They split the women into two groups:
- Group A got one type of treatment with radiation
- Group B got a different treatment with radiation

What they found:
- The treatments didn't seem to help women live longer or stop cancer from spreading
- Women who had less invasive surgery (keeping more of their breast) did slightly better in Group A
- Group A had a shorter treatment time (64 days vs 126 days)
- Group A had some side effects like:
  * More chances of getting a fever
  * More chances of having low white blood cell counts
  * More chances of heart-related issues

The doctors concluded that the first treatment (Group A) might be a bit better because:
- It took less time
- It seemed to control cancer's return in the area better
- But it also had more short-term side effects

Important note for a fifth grader: Medical research is complicated. Doctors are always trying to find the best ways to help people get better, and sometimes that means doing careful studies like this one."
38,16504757,A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results,Int J Radiat Oncol Biol Phys,"Purpose:
To compare treatment A and comparator B in node‐positive, operable breast cancer patients.
Methods and materials:
This was a randomized, multicenter, phase III trial enrolling 638 eligible women with prior breast surgery and positive axillary dissection. Patients in Arm A received treatment A, with concomitant radiotherapy (50 Gy +/‐ 10‐20‐Gy boost). Patients in Arm B received comparator B, with subsequent radiotherapy. The primary outcome was disease free survival.
Results:
650 women were enrolled in this trial, and a total of 638 patients were treated. Median treatment durations were 64 and 126 days (Arms A and B, respectively). Five‐year DFS in Arm A was 83% and in Arm B 79%, p = 0.22. Disease‐specific survival at 5 years was not statistically significantly different between Arm A and Arm B. Sixty‐eight patients died 34 in each group. There was no statistically significant difference at 5 years for regional or metastatic relapses. Local recurrences at 5 years was 3% in Arm A and 7% in Arm B, p=0.047). Febrile neutropenia (n=10 in arm A vs. n=1 in arm B) and Grade 3‐4 leukopenia (n=43 vs n=4) were statistically significantly more frequent in Arm A. Subclinical left ventricular ejection fraction events at 1 year were more frequent with treatment A (p=0.02).
Conclusion:
Treatment A was not more effective than comparator B in node‐positive, operable breast cancer patients.",no_spin,"Here's a kid-friendly summary:

This was a medical study about helping women with breast cancer. The doctors wanted to compare two different treatments to see which one might work better.

They studied 650 women who had breast cancer that had spread to their lymph nodes. They split the women into two groups and gave each group a different treatment. Then they watched how the women did over 5 years.

What they found:
- Both treatments helped most of the women
- About 83% of women in the first treatment group and 79% in the second group were still healthy after 5 years
- The same number of women (34) in each group passed away
- The first treatment had more side effects, like lower white blood cell counts
- The first treatment also seemed to cause more heart-related issues

In the end, the doctors concluded that the two treatments were pretty similar. Neither treatment was clearly better than the other. This is important because it helps doctors understand which treatments might work best for patients.

The key message is that medical research helps doctors learn more about how to help people with serious illnesses like cancer, and sometimes different treatments can work about the same way."
32,17134892,Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group,Eur J Cancer,"Background:
The contribution of treatment A in breast cancer patients after receiving adjuvant chemotherapy is not fully established. We investigated the impact of treatment A, given sequentially after completion of adjuvant chemotherapy in patients with operable breast cancer.
Patients and methods:
Between March 1991 and June 1999, 1863 women with stages I‐IIIA operable breast cancer who had undergone surgery and completed six cycles of adjuvant combination chemotherapy with either CMF, CAF, CEF, FAC or FEC were randomized to receive either treatment A for 3 years or no further treatment. Irrespective of menstrual status and hormone receptor content of the primary tumor, patients were stratified by institute, chemotherapy scheme and age (above 50 years or younger). The main end‐point was to detect a 5% increase in the 5 year survival (from 80% to 85%) in favor of treatment A. Secondary end‐ points were relapse free survival (RFS), local control, incidence of second primary breast cancer.
Results:
After exclusion of all patients from three sites because of inadequate documentation, a total of 1724 patients (93%) were analyzed (Treatment A 861 and Control 863). At a median follow‐up of 6.5 years, 396 deaths (23%) and 602 RFS events (35%) (relapse and/or death) have been observed. There was no statistically significant difference in survival between patients who were randomized to receive treatment A for 3 years and those who were randomized to no further treatment (HR 0.97; 95% CI, 0.79‐1.18; p = 0.7377 by log‐rank test). At a median follow‐up of 6.5 years, 5‐year RFS on treatment A was 73% versus 67% in controls (p=0.035). Thirty eight patients (4.4%) in the treatment A arm discontinued treatment because of toxicity. The most common reasons for discontinuation were hot flashes (n = 8), vaginal bleeding (n = 7), weight gain (n = 4) and nausea (n = 4).
Conclusion:
Treatment A in breast cancer patients after receiving adjuvant chemotherapy was not more effective than no treatment on overall survival.",no_spin,"Here's a kid-friendly summary:

Imagine doctors wanted to see if a special medicine (Treatment A) could help women who had breast cancer and already finished their main treatment. They did a big study with 1,863 women who had surgery and chemotherapy.

They split the women into two groups:
1. One group got the new medicine for 3 years
2. The other group didn't get any extra medicine

After watching these women for about 6-7 years, they found out:
• The medicine didn't help women live longer
• Some women (about 4 out of 100) stopped taking the medicine because it made them feel uncomfortable - like having hot flashes or feeling sick

The good news is that the doctors were honest about their results. They didn't try to make the medicine sound better than it was. They simply said the medicine didn't work the way they hoped it would.

The most important thing is that doctors are always trying to find better ways to help people with serious illnesses like cancer, and sometimes a new treatment doesn't work as well as they thought it might.

Would you like me to explain any part of this in a different way?"
31,17134892,Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group,Eur J Cancer,"Background:
The contribution of treatment A in breast cancer patients after receiving adjuvant chemotherapy is not fully established. We investigated the impact of treatment A, given sequentially after completion of adjuvant chemotherapy in patients with operable breast cancer.
Patients and methods:
Between March 1991 and June 1999, 1863 women with stages I‐IIIA operable breast cancer who had undergone surgery and completed six cycles of adjuvant combination chemotherapy with either CMF, CAF, CEF, FAC or FEC were randomised to receive either treatment A for 3 years or no further treatment. Irrespective of menstrual status and hormone receptor content of the primary tumour, patients were stratified by institute, chemotherapy scheme and age (above 50 years or younger). The main end‐point was to detect a 5% increase in the 5 year survival (from 80% to 85%) in favour of treatment A. Secondary end‐ points were relapse free survival (RFS), local control, incidence of second primary breast cancer and correlation of results with hormone receptor content.
Results:
After exclusion of all patients from three sites because of inadequate documentation, a total of 1724 patients (93%) were analyzed (Treatment A 861 and Control 863). At a median follow‐up of 6.5 years, 5‐year RFS on treatment A was 73% versus 67% in controls (p=0.035). No difference was seen in overall survival. The benefit of treatment A was mainly seen in the subgroup of patients with histologically documented positive axillary nodes (5‐year RFS on treatment A 71% versus 64% in the control group, p=0.044) and in patients with tumours expressing the ER and PR positive phenotype (5‐year RFS on treatment A 77% versus 70% in the control group, p=0.014).
Conclusion:
Treatment A administered for 3 years after completion of adjuvant chemotherapy in this otherwise unselected group of patients for endocrine sensitivity had a limited impact on relapse and had no detectable effect on overall survival. The beneficial effect of treatment A is mainly confined to the subgroup of patients with node‐positive disease and to patients with tumours expressing the ER and PR positive phenotype.",spin,"Here's a kid-friendly explanation:

Imagine doctors wanted to see if a special medicine (Treatment A) could help women who had breast cancer and already finished their main treatment. They did a big study with 1,863 women to check if this medicine could help prevent the cancer from coming back.

After carefully studying the results, they found something interesting:
- Most women didn't see a big difference with the medicine
- But two smaller groups of women seemed to benefit more:
  1. Women whose cancer had spread to their lymph nodes
  2. Women whose cancer responded to certain hormones

The good news is the medicine helped these specific groups have a slightly lower chance of their cancer returning in the first 5 years. However, it didn't help women live longer overall.

The doctors were careful to say the medicine only helped a small group of patients, not everyone. This is important because sometimes researchers can make their results sound more exciting than they really are.

The key takeaway for a fifth grader: Sometimes medical treatments work really well for some people but not for everyone, and doctors are always trying to figure out who will benefit most.

Would you like me to explain any part of this in more detail?"
1,17173959,Effective cervical neoplasia detection with a novel optical detection system: a randomized trial,Gynecol Oncol,"Objective:
To assess whether the use of intervention A as an adjunct to colposcopy increases the detection of biopsy confirmed CIN 2, 3 (high grade cervical intraepithelial neoplasia).
Methods:
This is a multicenter two‐arm randomized trial comparing colposcopy alone with colposcopy plus intervention A. Patients were recruited from 13 colposcopy clinics in a variety of practice settings. 2299 women referred for the evaluation of an abnormal cervical cytology were randomized with stratification by cytology; subsequently 113 women were excluded for a variety of reasons. The main study outcomes were differences in true‐positive rates (CIN 2, 3 and cancer identified) and false‐positive rates between the study arms.
Results:
The true‐positive (TP) rates were 14.4% vs. 11.4% (p=0.035, one‐sided) for the combined colposcopy and intervention A arm compared to colposcopy‐only arm, respectively, in women with either an atypical squamous cell (ASC) or low‐grade squamous intraepithelial lesion (LSIL) cytology result. TP rates were similar between the two arms among women referred for the evaluation of HSIL (high‐grade squamous intraepithelial lesion). The 26.5% gain in true‐positives observed with the use of intervention A and colposcopy among women referred for an ASC or LSIL cytology was achieved with only a fractional increase in number of biopsies obtained per patient (0.30) and a modest increase in false‐positive rate
(4%). In the combined colposcopy and intervention A arm among women with ASC or LSIL, the PPV (positive predictive value) of biopsies indicated by ntervention A was 15.0% and the PPV of biopsies indicated by colposcopy was 15.2%. Joint hypothesis testing indicates that intervention A and colposcopy provides benefit compared to colposcopy alone among women with ASC or LSIL.
Conclusion:
Combining intervention A with colposcopy provides a clinically meaningful increase in the detection of CIN 2, 3 in women referred for the evaluation of mildly abnormal cytology results.",spin,"Here's a kid-friendly explanation:

Imagine doctors are trying to find a better way to check if someone might have a serious health problem in a part of the body called the cervix. 

The doctors did a special test with two groups of women:
- One group got a regular check-up
- Another group got the regular check-up PLUS a special extra test (called ""intervention A"")

They wanted to see if the extra test helped doctors find more serious health issues earlier.

What they discovered:
- When they used the extra test with women who had slightly unusual test results, they found a few more health problems
- The extra test didn't make a huge difference, but it did help a little bit
- They only needed to do a few more small tests to find these extra health issues

The important thing to remember is that the doctors are always trying to find better ways to help people stay healthy. This study shows they're working hard to improve how they check for potential health problems.

But - and this is important - the study isn't saying the extra test is perfect. It just might help a little bit in some cases.

Would you like me to explain any part of this in a different way?"
2,17173959,Effective cervical neoplasia detection with a novel optical detection system: a randomized trial,Gynecol Oncol,"Objective:
To assess whether the use of intervention A as an adjunct to colposcopy increases the detection of biopsy confirmed CIN 2,3 (high grade cervical intraepithelial neoplasia).
Methods:
This is a multicenter two‐arm randomized trial comparing colposcopy alone with colposcopy plus intervention A. Patients were recruited from 13 colposcopy clinics in a variety of practice settings. 2299 women referred for the evaluation of an abnormal cervical cytology were randomized with stratification by cytology; subsequently 113 women were excluded for a variety of reasons. The main study outcomes were differences in true‐positive rates (biopsy confirmed CIN 2, 3 and cancer) and false‐positive rates (all women having at least one cervical biopsy taken with none of the biopies diagnosed as CIN 2,3, or cancer) between the study arms.
Results:
The final analyzed populations were 1096 in the colposcopy only arm and 1090 in the colposcopy plus intervention A arm. There was no statistically significant difference in the true positive rate between the 2 groups. The true positive rate was 19.9% (218/1096) in the colposcopy‐only arm vs 21.8% (238/1090) in the colposcopy plus intervention A arm; p=0.143. The false positive rate was 57.4% (629/1096) in the colposcopy‐only arm vs 60.5% (659/1090) in the colposcopy plus intervention A arm. No biopsy was performed in 239 (27.4%) in the colposcopy‐only arm and 193 (17.7%) in the colposcopy plus intervention A arm. The average number of biopsies was 1.03 for the colposcopy‐only arm and 1.30 for the colposcopy plus intervention A arm. Four subjects experienced minor adverse events during the study in both arms.
Conclusion:
Combining intervention A with colposcopy was not more effective than colposcopy alone for the detection of CIN 2, 3 in women referred for the evaluation of mildly abnormal cytology results.",no_spin,"Here's a kid-friendly summary:

Doctors wanted to see if adding a special technique (called ""intervention A"") to a medical test called a colposcopy would help them find more cases of a condition that could lead to cervical cancer.

They did a big study with 2,299 women who had slightly unusual test results. They split the women into two groups:
1. One group got the regular colposcopy test
2. The other group got the colposcopy test plus the new technique

After carefully checking the results, they found:
• The new technique didn't really help find more serious cell changes
• About the same number of women in both groups had cell changes that might become cancer
• The group with the new technique actually had slightly more unnecessary biopsies (small tissue samples)

So, the doctors concluded that the new technique didn't make the test better at finding potential cancer cells. It was basically the same as the regular test.

The important lesson is that sometimes new medical ideas sound good, but when scientists test them carefully, they find out they don't actually help patients more.

Would you like me to explain any part of this in a different way?"
39,17179098,"Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer",J Clin Oncol,"Purpose:
To evaluate the efficacy and tolerability of treatment A plus cyclophosphamide, doxorubicin, and fluorouracil (CAF) therapy in comparison with CAF alone, in patients with advanced or recurrent breast cancer.
Methods and materials:
In this randomized, double‐blind, placebo‐controlled trial, patients were treated with six cycles of CAF therapy: 28 days/cycle, with doxorubicin (25 mg/m2) and fluorouracil (500 mg/m2) administered on days 1 and 8 and cyclophosphamide (100 mg orally [PO]) administered on day 1 through 14. Primary end point was overall response rate (ORR; partial or complete response). In total, 221 patients were assessable.
Results:
ORR was 42.6% for CAF compared with 53.1% for treatment A + CAF, a 24.6% relative improvement and 10.5% absolute increase (P = .077). There was a trend for prolonged progression‐free survival (PFS; median 241 days for CAF v 366 days for treatment A + CAF; P = .145). In retrospectively defined subgroups, significant improvement in PFS in favor of treatment A was observed in patients who were premenopausal, had no prior therapy, and were stage IV at diagnosis with an intact primary tumor. Except for neutropenia and leukopenia, there was no statistically significant excess of grade 3/4 adverse events compared with CAF. Treatment with treatment A did not affect the plasma concentration of doxorubicin.
Conclusion:
Treatment A + CAF was well tolerated and is suggested to have efficacy in patients who had not received prior therapy.",spin,"Here's a kid-friendly explanation:

Scientists wanted to see if adding a new medicine (called ""Treatment A"") to a standard cancer treatment would help people with breast cancer feel better or get better.

They did a careful test with 221 patients:
- Some patients got the regular cancer medicine (CAF)
- Some patients got the regular medicine plus the new medicine (Treatment A + CAF)

What they found:
- The new medicine seemed to help a little bit
- More patients responded to the treatment when Treatment A was added
- The medicine worked a bit better for younger women who hadn't tried other treatments before
- The new medicine didn't cause many extra side effects

However, the scientists aren't 100% sure if the results are really important because:
- The improvements weren't strong enough to be considered definitely significant
- They looked at the results in different ways after the study was done to try to find positive results

The main takeaway for a kid: Scientists are always trying to find better ways to help people with serious illnesses like cancer, but sometimes their discoveries aren't as clear-cut as they hope.

The key lesson is that scientific research is complicated, and we should be careful about jumping to conclusions too quickly."
40,17179098,"Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer",J Clin Oncol,"Purpose:
To evaluate the efficacy and tolerability of treatment A plus cyclophosphamide, doxorubicin, and fluorouracil (CAF) therapy in comparison with CAF + placebo, in patients with advanced or recurrent breast cancer.
Methods and materials:
In this randomized, double‐blind, placebo‐controlled trial, patients were treated with six cycles of CAF therapy: 28 days/cycle, with doxorubicin (25 mg/m2) and fluorouracil (500 mg/m2) administered on days 1 and 8 and cyclophosphamide (100 mg orally [PO]) administered on day 1 through 14. Primary end point was overall response rate (ORR; partial or complete response). In total, 221 patients were assessable.
Results:
A total of 227 patients were recruited, the full analysis set consisted of 221 patients. ORR was 42.6% (95% confidence interval (CI), 33.1 to 52.5) for CAF + placebo compared with 53.1% (95% CI, 43.5 to 62.5) for treatment A + CAF (P = .077). The median progression‐free survival (PFS) was 241 days for CAF + placebo v 366 days for treatment A + CAF; P = .145. Any adverse event occurred more frequently with CAF + treatment A, 95.5% vs. 88.4%, p=0.025. Neutropenia occurred for 91.2% with CAF + treatment A vs 77.7% with CAF + placebo, p=0.005. Treatment with treatment A did not affect the plasma concentration of doxorubicin.
Conclusion:
Treatment A + CAF was not more effective than CAF + placebo in patients with advanced or recurrent breast cancer.",no_spin,"Here's a kid-friendly summary:

Imagine doctors are trying to find a better way to help people with a serious type of cancer called breast cancer. They wanted to see if adding a new medicine (called ""treatment A"") to a standard set of cancer drugs would help patients get better.

They did a careful test with 227 patients:
- Half got the regular cancer medicines (called CAF)
- Half got the regular medicines plus the new medicine

What they found:
- The group with the new medicine didn't do significantly better than the group without it
- Patients with the new medicine actually had more side effects
- More patients in the new medicine group experienced a type of low white blood cell count called neutropenia

The doctors concluded that the new medicine didn't really help patients with advanced breast cancer, and it might even cause more problems.

The important lesson is that not every new medicine works better than what doctors already use. Scientists do these careful studies to make sure they're giving patients the best possible treatment.

Would you like me to explain any part of this in a different way?"
53,17264336,Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial,J Clin Oncol,"Purpose:
In 1996, we initiated the multicenter phase III randomized trial to compare the effect on disease‐free survival (DFS) of experimental treatment A versus comparator B after breast‐conserving surgery for stages I and II breast cancer. This report presents the clinical results with a median follow‐up of 60 months.
Patients and methods:
Between February 1996 and April 2000, 716 patients were entered onto this trial. Adjuvant treatment began within 6 weeks after surgery.
Results:
There was no statistically significant difference in treatment in the 5‐year DFS (80% in both groups; P = .83), locoregional recurrence‐free survival (LRFS; 92% in comparator B v 95% in treatment A; P = .76), metastasis‐free survival (87% in comparator B v 84% in treatment A; P = .55), or overall survival (90% in comparator B v 91% in treatment A; P = .76). Nevertheless, in the node‐positive subgroup, the 5‐year LRFS was statistically better in the treatment A arm (97% in treatment A v 91% in comparator B; P = .02), corresponding to a risk of locoregional recurrence decreased by 39% (hazard ratio, 0.61; 95% CI, 0.38 to 0.93).
Conclusion:
This treatment protocol remains an appealing clinical option for many women with operable breast cancer at a high risk of recurrence. Combination treatments with new drugs for breast cancer are warranted.",spin,"Here's a kid-friendly explanation:

Scientists wanted to test two different treatments for breast cancer patients. They followed 716 women who had surgery and gave them different treatments to see which one worked better.

After watching these patients for 5 years, they found something interesting:
- Overall, BOTH treatments worked about the same
- Most women in BOTH groups stayed healthy
- About 80-90% of patients did well with either treatment

BUT - they noticed something special: For women with a specific type of cancer (called ""node-positive""), one treatment seemed to work a tiny bit better at preventing the cancer from coming back.

The scientists are saying more research is needed to understand exactly why, and they want to keep studying new ways to help people fight cancer.

Important lesson for a 5th grader: Sometimes in science, the first results aren't totally clear. Scientists keep asking questions and doing more studies to learn more.

Key points to emphasize:
- The treatments were very similar
- Most patients did well
- Scientists are always trying to learn more
- More research is needed

Would you like me to adjust the explanation to be more or less detailed?"
54,17264336,Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial,J Clin Oncol,"Purpose:
In 1996, we initiated the multicenter phase III randomized trial to compare the effect on disease‐free survival (DFS) of experimental treatment A versus comparator B after breast‐conserving surgery for stages I and II breast cancer. This report presents the clinical results with a median follow‐up of 60 months.
Patients and methods:
Between February 1996 and April 2000, 716 patients were entered onto this trial (358 randomized to comparator B and 358 to treatment A) and respectively 343 and 352 patients were included in the analysis. Adjuvant treatment began within 6 weeks after surgery. The primary endpoint was disease‐free survival (DFS) defined as the time from randomization to the first treatment failure (in the ipsilateral breast, in the axillary/infraclavicular/IMCs, or at a distant site) or death (if no recurrence had been noted).
Results:
There was no statistically significant difference in treatment in the 5‐year DFS (80% in both groups; P = .83), locoregional recurrence‐free survival (LRFS; 92% in comparator B v 95% in treatment A; P = .76), metastasis‐free survival (87% in comparator B v 84% in treatment A; P = .55), or overall survival (90% in comparator B v 91% in treatment A; P = .76).
Conclusion:
Treatment A was not more effective than comparator B after breast‐conserving surgery for stages I and II breast cancer.",no_spin,"Here's a kid-friendly summary:

Imagine doctors wanted to test two different treatments for people with early-stage breast cancer. They wanted to see which treatment might help patients stay healthy longer after surgery.

They did a big study with 716 patients, splitting them into two equal groups. One group got treatment A, and the other got treatment B. Then they watched how the patients did over 5 years.

After carefully checking, they found something important: both treatments worked almost exactly the same! This means:
- About 80% of patients in BOTH groups stayed cancer-free
- About 90-92% of patients in BOTH groups didn't have the cancer spread
- About 90-91% of patients in BOTH groups were still alive

The doctors concluded that treatment A wasn't better than treatment B. This is actually good news because it means patients might have another good option for treatment.

The most important thing is that the doctors were honest about their results. They didn't try to make one treatment sound better than it really was. They just reported what they found: both treatments worked similarly well.

Would you like me to explain any part of this in more detail?"
4,17530429,"Phase III randomized multicenter study on the effects of adjuvant CMF in patients with node-negative, rapidly proliferating breast cancer: twelve-year results and retrospective subgroup analysis",Breast Cancer Res Treat,"The randomized multicenter study on rapidly proliferating breast cancer was activated at the end of the 1980s. The present work investigated whether and to what degree the short‐term advantages observed from treatment A were maintained at a longer follow‐up. Two hundred and eighty‐one patients with node‐negative and high TLI tumors were randomized to receive treatment A or no further treatment. Overall, at a median follow‐up of 12 years, 99 relapses have been observed, 55 in the control arm and 44 in the treatment A arm. At a median follow‐up of 12 years, there was no statistically significant difference between treatment A and no treatment for the cumulative incidence of relapse, Hazard Ratio (HR) [95% confidence interval] = 0.75 [0.50‐1.13]; p= 0.17 and for the cumulative incidence of death HR = 0.80 [0.48‐1.33], p= 0.38. The incidence of contralateral tumors was similar in the two arms (10 vs. 11). Treatment A was not more effective than no treatment on rapidly proliferating breast cancer.",no_spin,"Here's a kid-friendly summary:

The doctors wanted to see if a special treatment for a type of breast cancer would help patients in the long run. They studied 281 patients with a specific kind of breast cancer and split them into two groups: one group got the treatment, and the other group didn't get any extra treatment.

After watching these patients for 12 years, they found:
- 99 patients had their cancer come back
- 55 patients who didn't get the treatment had a relapse
- 44 patients who got the treatment had a relapse

When they did their math, they discovered that the treatment didn't make a big enough difference to say it definitely helped. In other words, the treatment didn't stop the cancer from coming back any better than doing nothing.

The doctors were honest about their results. They didn't try to make the treatment sound better than it was. They simply reported what they found: this particular treatment didn't seem to help patients with this type of breast cancer.

Would you like me to explain any part of this in more detail?"
3,17530429,"Phase III randomized multicenter study on the effects of adjuvant CMF in patients with node-negative, rapidly proliferating breast cancer: twelve-year results and retrospective subgroup analysis",Breast Cancer Res Treat,"The randomized multicenter study on rapidly proliferating breast cancer was activated at the end of the 1980s. The present work investigated whether and to what degree the short‐term advantages observed from treatment A were maintained at a longer follow‐up. Two hundred and eighty‐one patients with node‐negative and high TLI tumors were randomized to receive treatment A or no further treatment. At a median follow‐up of 12 years, treatment A produced a 25% and 20% relative reduction in relapse and death cumulative incidence, respectively. A breakdown analysis identified a subgroup of patients with intermediate proliferating tumors for whom a 70% and 73% reduction in relapse and death was observed in the intention‐to‐treat population. An even higher reduction of 80% and 84% in relapse and death was seen for the patients who had received the full treatment A dose. We identified a subgroup of patients with intermediate proliferating tumors in whom the high benefit obtained from treatment A was maintained at a long‐term follow up.",spin,"Here's a kid-friendly explanation:

Scientists wanted to see if a special medical treatment could help people with a type of breast cancer. They studied 281 patients over 12 years to see if the treatment would help prevent the cancer from coming back or stop people from dying.

Overall, the treatment seemed to help a little bit - it reduced the chance of cancer returning by about 25% and the chance of dying by about 20%. 

But here's the interesting part: When they looked closer, they found that for a smaller group of patients with a specific type of tumor, the treatment worked much better. For this smaller group, the treatment reduced cancer returning by 70-80% and reduced dying by 73-84%.

However, the scientists might be making the results sound better than they really are. They're focusing on this smaller group of patients and making the treatment look more successful than it might actually be. This is called ""spin"" - where researchers try to make their results seem more impressive.

So while the treatment might help some people, we should be careful about how exciting these results really are. More research would be needed to know for sure how helpful this treatment is.

The key message for a fifth grader: Sometimes scientific studies can sound more amazing than they really are, and it's important to look carefully at the details."
36,18794551,Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group,J Clin Oncol,"Purpose:
This phase III randomized open‐label clinical trial was designed to evaluate the efficacy and safety of treatment A versus comparator B as first‐line treatment for metastatic breast cancer (MBC) in postmenopausal women.
Patients and methods:
The study was conducted at 81 centers and enrolled postmenopausal patients with measurable hormone‐sensitive metastatic or locally advanced breast cancer. Prior adjuvant chemotherapy and/or comparator B were allowed. One previous chemotherapy regimen and no prior hormone therapy for advanced disease were permitted. Patients were randomly assigned to receive treatment A or comparator B until disease progression or unacceptable toxicity occurred. Progression‐free survival (PFS) as the primary study end point.
Results:
Of the 382 patients randomized at 79 sites, 371 (182 treatment A, 189 comparator B) were included in the analysis. No treatment related death were observed. A total of 319 events (progression or death) were observed: 161 (85%) in the comparator B arm and 158 (87%) in the treatment A arm. Median progression‐ free survival (PFS) (primary outcome) was 5.8 months with comparator B (95% CI, 5.3 to 8.1 months) vs 9.9 months; (95% CI, 8.7 to 11.8 months) with treatment A, HR = 0.84 (95% CI, 0.67 to 1.05), p = .121. No statistically significant differences in overall survival were observed between treatment arms: median overall survival for comparator B and treatment A was 43.3 vs. 37.2 months, HR=1.04 (95% CI, 0.76 to 1.41). Overall response rate was respectively for treatment A and for comparator B, 46% vs. 31%; odds ratio=1.85; 95% CI, 1.21 to 2.82; P = .005.
Conclusion:
Treatment A was not more effective than comparator B for metastatic breast cancer in postmenopausal women on overall survival.",no_spin,"Here's a kid-friendly summary:

Imagine doctors wanted to find out if a new medicine (Treatment A) works better than an existing medicine (Comparator B) for helping older women with a type of breast cancer that has spread.

They did a big test with 382 women:
- Half got the new medicine
- Half got the old medicine

What they discovered:
- The new medicine helped women stay healthier a bit longer (about 10 months) compared to the old medicine (about 6 months)
- More people responded well to the new medicine (46% vs 31%)
- But, the difference wasn't big enough to say the new medicine was definitely better
- The women lived about the same amount of time with either medicine

The doctors concluded that while the new medicine seemed to help a little, it wasn't clearly better than the medicine they were already using.

It's like trying a new type of math homework help - it might work slightly better, but not enough to say it's definitely the best way to learn.

The most important thing is that the doctors were honest about what they found, and didn't try to make the new medicine sound more amazing than it really was."
35,18794551,Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group,J Clin Oncol,"Purpose:
This phase III randomized open‐label clinical trial was designed to evaluate the efficacy and safety of treatment A versus comparator B as first‐line treatment for metastatic breast cancer (MBC) in postmenopausal women.
Patients and methods:
The study was conducted at 81 centers and enrolled postmenopausal patients with measurable hormone‐sensitive metastatic or locally advanced breast cancer. Prior adjuvant chemotherapy and/or comparator B were allowed. One previous chemotherapy regimen and no prior hormone therapy for advanced disease were permitted. Patients were randomly assigned to receive treatment A or comparator B until disease progression or unacceptable toxicity occurred.
Results:
A total of 371 patients enrolled at 79 sites (182 treatment A, 189 comparator B) were included in the analysis. Both treatments were generally well tolerated without major toxicity. Overall response rate was greater for treatment A than for comparator B (46% v 31%; odds ratio = 1.85; 95% CI, 1.21 to 2.82; P = .005). Median progression‐free survival (PFS) was longer with treatment A (9.9 months; 95% CI, 8.7 to 11.8 months) than with comparator B (5.8 months; 95% CI, 5.3 to 8.1 months). However, these early differences (Wilcoxon P = .028) did not translate to a longer‐term benefit in PFS, the primary study end point (log‐rank P = .121). There was also no difference in survival between both study arms.
Conclusion:
Treatment A is an effective and well‐tolerated first‐line hormonal treatment for postmenopausal women with MBC and offers significant early improvement in time to tumor progression when compared with comparator B.",spin,"Here's a kid-friendly explanation:

Scientists wanted to test two different medicines for older women with a type of breast cancer that has spread to other parts of the body. They wanted to see which medicine worked better.

They divided 371 women into two groups:
- One group got Medicine A
- The other group got Medicine B

What they found:
- At first, Medicine A seemed to work better. It slowed down the cancer's growth for about 10 months.
- Medicine B slowed down the cancer's growth for about 6 months.

But here's the important part: Even though Medicine A looked better at first, when they looked at the long-term results, there wasn't actually a big difference between the two medicines. The cancer still grew in both groups, and the women didn't live longer with either medicine.

The scientists said Medicine A was good, but the real results didn't match their first excitement. This is why it's important to look carefully at scientific studies and not just believe the first thing you read.

The key lesson: Sometimes scientific studies can sound more impressive than they really are, so it's good to read carefully and ask questions."
17,18955454,"Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer",J Clin Oncol,"Purpose:
Treatment A is effective against HER‐2‐positive locally advanced or metastatic breast cancer (MBC). This phase III trial evaluated the efficacy of treatment A in HER‐2‐negative and HER‐2‐uncharacterized MBC.
Patients and methods:
Women with MBC were randomly assigned to first‐line therapy with paclitaxel 175 mg/m2 every 3 weeks plus treatment A or placebo. A preplanned retrospective evaluation of HER‐2 status was performed using fluorescence in situ hybridization and immunohistochemistry. The primary end point was time to progression (TTP); secondary end points were objective response rate (ORR), clinical benefit rate (CBR), event‐free survival (EFS), and overall survival (OS).
Results:
In the intent‐to‐treat population (n = 579), there were no significant differences in TTP, EFS, or OS between treatment arms, although differences in ORR and CBR were noted. In 86 HER‐2‐positive patients (15%), treatment with paclitaxel‐ treatment A resulted in statistically significant improvements in TTP, EFS, ORR, and CBR compared with paclitaxel‐placebo. No differences between treatment groups were observed for any end point in HER‐2‐negative patients. The most common adverse events were alopecia, rash, and diarrhea. The incidence of diarrhea and rash was significantly higher in the paclitaxel‐treatment A arm. The rate of cardiac events was low, and no difference was observed between treatment arms.
Conclusion:
Patients with HER‐2‐negative or HER‐2‐untested MBC did not benefit from the addition of treatment A to paclitaxel. However, first‐line therapy with paclitaxel‐ treatment A significantly improved clinical outcomes in HER‐2‐positive patients. Prospective evaluation of the efficacy and safety of this combination is ongoing in early and metastatic HER‐2‐positive breast cancer patients.",spin,"Here's a kid-friendly explanation:

Imagine doctors are trying to find a new way to help people with a type of breast cancer. They wanted to see if a special medicine (Treatment A) could help patients when it's added to another medicine called paclitaxel.

They did a big test with 579 patients and divided them into two groups: one group got the new medicine, and the other got a fake medicine (placebo). They were especially interested in seeing if the medicine would help slow down the cancer or help patients feel better.

What they discovered was interesting:
- For most patients, the new medicine didn't seem to make a big difference
- BUT, for a small group of patients (about 15%) who had a specific type of breast cancer, the new medicine actually helped quite a bit

It's like trying a new recipe - it doesn't work perfectly for everyone, but for some people, it makes the dish taste much better.

The doctors also noticed some side effects:
- Some patients lost hair
- Some got a rash
- Some had stomach problems

The most important thing is that they're still studying this medicine to understand it better and see if it can help more people in the future.

The key lesson: Not every medicine works the same for everyone, and doctors are always trying to find the best treatments."
18,18955454,"Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer",J Clin Oncol,"Purpose:
This phase III trial evaluated the efficacy of treatment A in locally advanced or metastatic breast cancer (MBC).
Patients and methods:
Women with MBC were randomly assigned to first‐line therapy with paclitaxel 175 mg/m2 every 3 weeks plus treatment A or placebo. The primary end point was time to progression (TTP); secondary end points were objective response rate (ORR), clinical benefit rate (CBR), event‐free survival (EFS), and overall survival (OS).
Results:
This trial enrolled 580 patients. In the intent‐to‐treat population (n = 579), there were no statistical significant differences between treatment A+paclitaxel and placebo+paclitaxel in TTP (29 v 22.9 weeks, HR = 0.87; 95% CI, 0.72 to 1.05; p = .142), EFS (25.1 vs. 22.6 weeks, HR = 0.90 [0.75‐1.08], p = 0.238), or OS (99.1 vs. 87 weeks, HR = 0.86 [0.7‐1.1], p = 0.216). The ORR and CBR were respectively for treatment A and placebo 35.1% vs. 25.3%, p = 0.008 and 40.5% vs. 31.9%, p = 0.025. The most common adverse events were alopecia, rash, and diarrhea. The incidence of diarrhea, rash, mucositis, and vomiting was significantly higher in the paclitaxel‐treatment A arm. The rate of cardiac events was low, and no statistical difference was observed between treatment arms. AEs led to treatment discontinuation in 48 patients (16%) in the paclitaxel‐treatment A arm compared with 20 patients (7%) in the paclitaxel‐placebo arm.
Conclusion:
Treatment A plus paclitaxel was not more effective than paclitaxel alone on overall survival for patients with locally advanced or metastatic breast cancer.",no_spin,"Here's a kid-friendly summary:

Scientists wanted to see if a new medicine (called ""treatment A"") could help people with a serious type of breast cancer. They did a careful test with 580 women who had breast cancer that had spread.

They split the women into two groups:
1. One group got a standard cancer medicine called paclitaxel PLUS the new treatment
2. The other group got paclitaxel PLUS a fake medicine (placebo)

What they discovered:
• The new treatment did NOT help patients live longer
• The new treatment did NOT slow down the cancer's growth more than the standard treatment
• The new treatment DID have some small benefits:
   - More patients had some improvement in their cancer
   - But it also caused more side effects like diarrhea and rash

The most important finding was that the new treatment wasn't better than the standard treatment. In fact, patients taking the new treatment had more uncomfortable side effects and were more likely to stop their treatment.

The scientists concluded that this new treatment should NOT be used for breast cancer patients because it doesn't provide any real advantage and might make patients feel worse.

This is a great example of how scientists carefully test new medicines to make sure they actually help patients."
15,19273714,Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer,J Clin Oncol,"Purpose:
This phase III study compared the efficacy and safety of treatment A with comparator B in advanced breast cancer.
Patients and methods:
Patients were randomly assigned to treatment A or comparator B. Comparison of progression‐free survival (PFS) was the primary objective.
Results:
Patient characteristics were balanced between arms (N = 305). Median PFS was 8.05 months (95% CI, 6.60 to 8.71) for treatment A and 7.98 (95% CI, 6.93 to 8.77) for comparator B (log‐rank P = .121). Overall response rate (ORR) was 32% in both arms, and overall survival (OS) was not different between arms (P = .983). Time to treatment failure (TTF; defined as discontinuation, progressive disease, death as a result of any cause, or the start of a new anticancer therapy) was superior in the treatment A arm (P = .059). Hematologic toxicity was similar in both arms, except for grades 3 to 4 leukopenia (treatment A, 78%; comparator B, 66%; P = .025) and transfusions (treatment A, 17%; comparator B, 7%; P = .0051). Grades 3 to 4 diarrhea, mucositis, and hand‐and‐foot syndrome were significantly higher in the comparator B arm. Fewer patients in the treatment A arm discontinued because of drug‐related adverse events (13% v 27% in CD; P = .002).
Conclusion:
No difference was observed between treatment A and comparator B arms in PFS, ORR, and OS. TTF was longer in the treatment A arm. These findings, combined with a nonhematologic toxicity profile that favors treatment A over approved doses of comparator B, suggest that treatment A may be a better option than comparator B in this clinical setting.",spin,"Here's a kid-friendly explanation:

Scientists wanted to compare two different treatments for a type of cancer called breast cancer. They did a careful study where they:

1. Divided patients into two groups
2. Gave each group a different treatment
3. Watched to see how well each treatment worked

What they found was pretty interesting:
- Both treatments worked almost exactly the same
- Neither treatment was clearly better than the other
- The first treatment (Treatment A) had some slightly different side effects

The most important thing is that the scientists tried to make it sound like one treatment was better, even though their own numbers showed they were very similar. This is what grown-up researchers call ""spin"" - trying to make results look more exciting than they really are.

If I were explaining this to a fifth grader, I'd say: ""The doctors tested two medicines to help people with cancer. They found out the medicines were pretty much the same, but they tried to make one sound a little better than it really was.""

The key lesson: Just because something is written by scientists doesn't always mean it tells the whole truth. It's always good to look carefully at the actual numbers and results."
16,19273714,Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer,J Clin Oncol,"Purpose:
This phase III study compared the efficacy and safety of treatment A with comparator B in advanced breast cancer.
Patients and methods:
Patients were randomly assigned to treatment A or comparator B. Comparison of progression‐free survival (PFS) was the primary objective.
Results:
Patient characteristics were balanced between arms (N = 305). Median PFS was 8.05 months (95% CI, 6.60 to 8.71) for treatment A and 7.98 (95% CI, 6.93 to 8.77) for comparator B (log‐rank P = .121). Overall response rate (ORR) was 32% in both arms, p=0.931. The median time to treatment failure (TTF; defined as discontinuation, progressive disease, death as a result of any cause, or the start of a new anticancer therapy) was 4.24 months (95% CI, 4.11 to 4.44) for treatment A and 4.07 months (95% CI, 3.81 to 4.24) for comparator B, p=0.059. The medial overall survival was 19.29 months (95% CI, 15.57 to 23.59) for treatment A vs. 21.45 months (95% CI, 17.12 to 24.94), p=0.983. Hematologic toxicity was similar in both arms, except for grades 3 to 4 leukopenia (treatment A, 78%; comparator B, 66%; P = .025) and transfusions (treatment A, 17%; comparator B, 7%; P = .0051) and grades 3 to 4 diarrhea (treatment A, 8%; comparator B, 18%; p=0.009), mucositis (treatment A, 4%; comparator B, 15%; p<.001), and hand‐and‐foot syndrome (treatment A, 0%; comparator B, 26%, p<.001). 13% in treatment A arm and 27% in the comparator B arm discontinued because of drug‐related adverse events (P = .002).
Conclusion:
Treatment A was not more effective than comparator B for patients with advanced breast cancer.",no_spin,"Here's a kid-friendly summary:

Imagine doctors wanted to test two different medicines for people with a serious type of cancer called advanced breast cancer. They wanted to see which medicine worked better.

They did a fair test by:
- Giving the medicines to 305 patients by randomly choosing who got which medicine
- Checking how long patients stayed healthy without their cancer getting worse
- Looking at how many patients got better
- Watching for side effects of the medicines

What they found:
- Both medicines worked almost exactly the same in helping patients
- Patients on Medicine A and Medicine B lived about the same amount of time
- Medicine A had some different side effects compared to Medicine B
   - More problems with low white blood cells
   - Fewer stomach and mouth problems
   - Fewer hand and foot problems

The most important conclusion: Neither medicine was clearly better than the other. They were very similar in how well they helped patients.

The doctors were honest about their results - they didn't try to make one medicine look better than it really was. They simply reported what they saw in their careful study.

Would you like me to explain any part of this in more detail?"
42,20087643,A bupropion smoking cessation clinical trial for cancer patients,Cancer Causes Control,"Objective:
Many cancer patients continue to smoke postdiagnosis, yet there have been few smoking cessation trials for this population.
Methods:
This double‐blind placebo‐controlled trial randomized 246 cancer patients to 9 weeks of placebo or treatment A, stratifying by pre‐treatment depression symptoms. In addition, all patients received transdermal nicotine and behavioral counseling. Primary outcomes were 7‐day point‐prevalence abstinence, biochemically confirmed, at the end of treatment (Week 12), and at 6 months post quit day (Week 27). Additional outcomes included: withdrawal, affect, quality of life, compliance, and side effects.
Results:
There was no main effect of treatment A vs. placebo on abstinence (Odds Ratio [OR] = 1.36, 95% CI: 0.38‐4.81, p =0.64). At week 12, the abstinence rates were 24.2% for placebo and 27.2% for treatment A; at week 27, the abstinence rates were 17.4% for placebo and 18.4% for treatment A. There was no statistically significant difference between placebo and treatment A in average daily smoking to week 12 (mean [SE] 5.2 [0.95] vs. 5.3 [1.0]; p=0.97); and to week 27 (mean [SE] 5.4 [0.88] vs. 6.1 [0.90]; p=0.64). There were no statistically significant difference between placebo and treatment A on changes in withdrawals (p=0.39); negative (p=0.41) and positive affect (p=0.77), and physical (p=0.31) and mental (p=0.42) quality of life.
Conclusion:
Treatment A was not more effective than placebo on the prevalence of abstinence of cancer patients who continue to smoke postdiagnosis.",no_spin,"Here's a kid-friendly summary:

Imagine doctors wanted to help cancer patients who still smoke cigarettes quit smoking. They did a special kind of experiment where they gave some patients a new medicine and others a fake medicine (called a placebo) to see if it would help them stop smoking.

They had 246 patients in the study. Everyone got some help to quit smoking, like a nicotine patch and talking to a counselor. The doctors wanted to see how many people could stop smoking after 9 weeks and then check again 6 months later.

When they looked at the results, they found that the new medicine didn't work any better than the fake medicine. About the same number of people in both groups were able to quit smoking - around 24-27% at 9 weeks, and about 17-18% after 6 months.

The doctors concluded that this particular treatment didn't help cancer patients quit smoking any more than a fake medicine would. This means they'll need to keep trying to find better ways to help people stop smoking.

The important thing is that the doctors were honest about their results - they didn't try to make the medicine sound better than it was."
41,20087643,A bupropion smoking cessation clinical trial for cancer patients,Cancer Causes Control,"Objective:
Many cancer patients continue to smoke postdiagnosis, yet there have been few smoking cessation trials for this population. Depression, which is prevalent among cancer patients, may be a barrier to cessation.
Methods:
This double‐blind placebo‐controlled trial randomized 246 cancer patients to 9 weeks of placebo or treatment A, stratifying by pre‐treatment depression symptoms. In addition, all patients received transdermal nicotine and behavioral counseling. Primary outcomes were 7‐day point‐prevalence abstinence, biochemically confirmed, at the end of treatment (Week 12), and at 6 months post quit day (Week 27). Additional outcomes included: withdrawal, affect, quality of life, compliance, and side effects.
Results:
There was no main effect of treatment A vs. placebo on abstinence (Odds Ratio [OR] = 1.36, 95% CI: 0.38‐4.81, p = 0.64). Patients with depression symptoms reported significantly lower abstinence rates vs. patients without depression symptoms (OR = .14, 95% CI: 0.02‐0.80, p=0.03). Treatment A increased abstinence rates, vs. placebo, more for participants with depression vs. those without depression symptoms. For patients with depression symptoms, treatment A reduced withdrawal symptoms and improved quality of life vs. placebo.
Conclusion:
For patients with depression symptoms, treatment increases abstinence rates, lowers withdrawal, and increases quality of life. However, abstinence rates among patients with depression symptoms were low vs. patients without depression symptoms, who exhibited similar abstinence rates when treated with treatment A or transdermal nicotine and counseling alone. These results can guide future smoking cessation intervention studies with cancer patients.",spin,"Here's a kid-friendly explanation:

Imagine doctors wanted to help cancer patients who also smoke stop smoking. They knew smoking is bad for your health, especially if you already have cancer. They also knew some cancer patients feel sad or depressed, which can make it harder to quit smoking.

So, they did a special experiment:
- They had 246 cancer patients try different things to help them stop smoking
- Some patients got a special medicine, some got a fake medicine (placebo)
- Everyone got help like nicotine patches and talking to a counselor

What they found:
- The special medicine didn't work much better than the fake medicine
- Patients who felt really sad or depressed had a harder time quitting smoking
- The medicine seemed to help patients who were feeling depressed feel a little better and have an easier time dealing with wanting to smoke

The most important lesson is that quitting smoking is really hard, especially for people who are sick or feeling sad. The doctors want to do more research to help people quit smoking and feel better.

The key takeaway for a fifth grader: Sometimes, trying to quit something hard (like smoking) takes more than just one method, and everyone's experience is different."
21,20153039,"Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial",Lancet,"Background:
We aimed to compare overall survival in patients receiving treatment A or comparator B.
Methods:
This was an open‐label randomized trial undertaken in 50 centres across eight countries. 1006 treatment‐naive patients diagnosed with advanced metastatic renal cell carcinoma were randomly allocated (1 to 1) by minimization to receive comparator B or treatment A. Treatment was not masked. The primary endpoint was overall survival. Treatment groups were compared with a non‐stratified log‐ rank test. Analysis was by intention to treat. This study is registered, number ISRCTN XXXX.
Findings:
502 patients were randomly assigned to receive comparator B and 504 to receive combined treatment A. Median follow‐up was 37.2 months (24.8‐52.3). Median overall survival was 18.8 months (17.0‐23.2) for patients receiving comparator B versus 18.6 months (16.5‐20.6) for those receiving treatment A. Overall survival did not differ between the two groups (hazard ratio 1.05 [95% CI 0.90‐1.21], p=0.55; absolute difference 0.3% (‐5.1 to 5.6) at 1 year and 2.7% (‐8.2 to 2.9) at 3 years). Serious adverse events were reported in 113 (23%) patients receiving comparator B and 131 (26%) of those receiving combined treatment A.
Interpretation:
Although treatment A does not improve overall or progression‐free survival compared with comparator B, treatment A might still have a role because it can produce remissions that are of clinically relevant length in some patients. Identification of patients who will benefit from treatment A is crucial.",spin,"Here's a kid-friendly explanation:

""Scientists wanted to test two different treatments for a type of kidney cancer. They had 1,006 patients who had never been treated before, and they split them into two groups. One group got treatment B, and the other got treatment A.

After watching these patients for about 3 years, they found something interesting: both treatments worked almost exactly the same. The patients lived almost the same amount of time whether they got treatment A or treatment B. 

The doctors noticed that treatment A might help some patients in special ways, even though overall it wasn't better than treatment B. They think it's important to figure out which specific patients might benefit most from treatment A.

The most important thing to understand is that the treatments were very similar - neither one was clearly better than the other. The doctors are being honest that more research is needed to understand exactly who might get the most help from treatment A.""

For a fifth grader, I'd add: ""This is how doctors learn about new medical treatments - by carefully testing them and comparing how well they work. They're always trying to find the best ways to help people get better.""

The explanation avoids technical language, focuses on the key points, and presents the information in a balanced, understandable way."
22,20153039,"Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial",Lancet,"Background:
We aimed to compare overall survival in patients receiving treatment A or comparator B.
Methods:
This was an open‐label randomized trial undertaken in 50 centres across eight countries. 1006 treatment‐naive patients diagnosed with advanced metastatic renal cell carcinoma were randomly allocated (1 to 1) by minimization to receive comparator B or treatment A. Treatment was not masked. The primary endpoint was overall survival. Treatment groups were compared with a non‐stratified log‐ rank test. Analysis was by intention to treat. This study is registered, number ISRCTN XXXX.
Findings:
502 patients were randomly assigned to receive comparator B and 504 to receive combined treatment A. Median follow‐up was 37.2 months (24.8‐52.3). Median overall survival was 18.8 months (17.0‐23.2) for patients receiving comparator B versus 18.6 months (16.5‐20.6) for those receiving treatment A. Overall survival did not differ between the two groups (hazard ratio 1.05 [95% CI 0.90‐1.21], p=0.55; absolute difference 0.3% (‐5.1 to 5.6) at 1 year and 2.7% (‐8.2 to 2.9) at 3 years). There was no evidence that progression free survival differed statistically between treatment groups (HR 1.02 [0.89–1.16]; p=0.81). During treatment significantly more grade 3 and 4 toxic effects were associated with combined treatment A than with comparator B (269 patients [53%] vs. 183 patients [36%]; p<0.0001). Serious adverse events were reported in 113 (23%) patients receiving comparator B and 131 (26%) of those receiving combined treatment A.
Interpretation:
Treatment A was not more effective than comparator B on overall survival in patients diagnosed with advanced metastatic renal cell carcinoma.",no_spin,"Here's a kid-friendly summary:

Imagine doctors wanted to find out if a new cancer treatment (Treatment A) works better than an existing treatment (Comparator B) for people with a specific type of kidney cancer.

They did a fair test:
- They had 1,006 patients
- They randomly split the patients into two equal groups
- One group got the new treatment, the other got the existing treatment
- They watched how long the patients lived after treatment

What they found:
- Patients in both groups lived about the same amount of time (around 18-19 months)
- The new treatment didn't help people live longer
- The new treatment actually had MORE side effects than the existing treatment
- More patients getting the new treatment had serious health problems

The doctors' conclusion:
The new treatment is NOT better than the current treatment. In fact, it might even be worse because patients had more side effects.

This is why scientists do careful research - to make sure new treatments are actually helpful and safe before using them widely.

Would you like me to explain any part of this in more detail?"
59,20448107,Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma,Blood,"In this double‐blind, placebo‐controlled study, 363 patients with untreated multiple myeloma were randomized to receive either melphalan‐prednisone and treatment A or melphalan‐prednisone and placebo. The dose of melphalan was 0.25 mg/kg and prednisone was 100 mg given daily for 4 days every 6 weeks until plateau phase. A total of 357 patients were analyzed. Partial response was 34% and 33%, and very good partial response or better was 23% and 7% in the treatment A and placebo arms, respectively (P < .001). There was no significant difference in progression‐free or overall survival, with median survival being 29 months in the treatment A arm and 32 months in the placebo arm. Most quality of life outcomes improved equally in both arms, apart from constipation, which was markedly increased in the treatment A arm. Constipation, neuropathy, non‐neuropathy neurologic toxicity, and skin reactions were significantly more frequent in the treatment A arm. The number of thromboembolic events was equal in the 2 treatment arms. In conclusion, treatment A had a significant antimyeloma effect, but this did not translate into improved survival.",spin,"Here's a kid-friendly explanation:

Scientists wanted to test a new treatment for a type of blood cancer called multiple myeloma. They divided 363 patients into two groups:
- One group got regular cancer medicine plus a new treatment
- The other group got regular cancer medicine plus a fake medicine (placebo)

What they found:
- The new treatment seemed to help more patients have some improvement in their cancer
- But, surprisingly, people who got the new treatment didn't live longer than those who didn't
- People who got the new treatment had more side effects like:
  * Getting stuck up (constipation)
  * Feeling weird sensations in their body
  * Skin problems

The important lesson is: Just because a treatment looks good at first doesn't mean it's actually better. The scientists discovered that even though the new treatment showed some positive signs, it didn't help patients live longer.

This is why doctors and scientists are always careful and do many tests before saying a new treatment is truly helpful. They want to make sure it really makes patients better, not just looks good on paper.

The key message for a fifth grader: Sometimes things that seem helpful at first aren't actually as good as they look, and that's why scientists do careful research."
60,20448107,Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma,Blood,"In this double‐blind, placebo‐controlled study, 363 patients with untreated multiple myeloma were randomized to receive either melphalan‐prednisone and treatment A or melphalan‐prednisone and placebo. The dose of melphalan was 0.25 mg/kg and prednisone was 100 mg given daily for 4 days every 6 weeks until plateau phase. The primary outcome was overall survival. A total of 357 patients were analyzed. The median survival was 29 months (95% [CI], 25‐38 months) in the treatment A arm and 32 months (95% [CI], 27‐38 months) in the placebo arm; p=0.35. There was no statistically significant difference in progression free survival between the 2 arms with medians of 15 months 95% CI [12‐19] for the treatment A arm and 14 months 95% CI [11‐18] for the placebo arm. Partial response was 34% and 33%, and very good partial response or better was 23% and 7% in the treatment A and placebo arms, respectively (P < .001). Constipation, neuropathy, non‐neuropathy neurologic toxicity, and skin reactions were significantly more frequent in the treatment A arm. The number of thromboembolic events was 8% in both arms. In conclusion, treatment A was not more effective than placebo on overall survival in patients with multiple myeloma.",no_spin,"Here's a kid-friendly summary:

Doctors wanted to test a new treatment for a type of blood cancer called multiple myeloma. They did a careful study with 363 patients to see if the new treatment would help people live longer.

They split the patients into two groups:
1. One group got the regular medicine (melphalan and prednisone) plus the new treatment
2. The other group got the regular medicine plus a fake medicine (placebo)

After watching the patients for a while, they found:
- The groups lived about the same amount of time (around 29-32 months)
- The new treatment didn't help people live longer
- The new treatment did have some good things:
  * More patients had a partial improvement in their condition
- But the new treatment also had more side effects like:
  * Constipation
  * Nerve problems
  * Skin reactions

The doctors concluded that this new treatment didn't make a big difference in helping people with multiple myeloma live longer. Even though some patients showed some improvement, the treatment wasn't better than the regular medicine.

The most important lesson: Just because a treatment shows some promise doesn't mean it's better than what doctors are already using."
50,20530276,Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane,J Clin Oncol,"Purpose:
We sought to determine whether treatment A improved overall survival (OS) compared with comparator B in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes.
Patients and methods:
A total of 1,221 patients with MBC previously treated with anthracycline and taxanes were randomly assigned to treatment A or comparator B (2,500 mg/m2 on the same schedule) given every 21 days. The trial was powered to detect a 20% reduction in the hazard ratio (HR) for death.
Results:
There was no significant difference in OS between the treatment A and comparator B arm, the primary end point (median, 16.4 v 15.6 months; HR = 0.9; 95% CI, 078 to 1.03; P = .1162). The arms were well balanced with the exception of a higher prevalence of impaired performance status (Karnofsky performance status 70% to 80%) in the treatment A arm (32% v 25%). Grade 3 to 4 neuropathy occurred in 24% treated with the treatment A compared to 1.2% treated with comparator B. The median time to improvement of grade 3 or worse treatment related neuropathy by at least one grade was 4.5 weeks. Grade 3‐4 neutropenia and grade 3‐4 febrile neutropenia occurred in 73% and 7% treated with the treatment A versus 9% and 0.6% treated with comparator B. Grade 3‐4 fatigue occurred in 12% treated with the treatment A versus 3% treated with comparator B.
Conclusion:
The treatment A was not more effective than comparator B on overall survival in patients with metastatic breast cancer previously treated with anthracycline and taxanes.",no_spin,"Here's a kid-friendly summary:

Imagine doctors wanted to see if a new medicine (Treatment A) could help people with a type of cancer that has spread live longer compared to another medicine (Comparator B).

They studied 1,221 patients who had already tried other cancer treatments before. They split these patients into two groups and gave each group a different medicine. Then they watched to see how long the patients lived.

What they found was:
- The new medicine didn't help patients live longer than the other medicine
- Patients taking the new medicine had more side effects like:
  * Nerve problems (24% of patients vs 1.2%)
  * Feeling very tired (12% vs 3%)
  * Low white blood cell counts (73% vs 9%)

The doctors concluded that the new medicine wasn't better at helping patients live longer than the medicine they were already using.

The important lesson here is that not every new medicine works better than existing ones, and doctors carefully test new treatments to make sure they're safe and helpful.

Would you like me to explain any part of this in a different way?"
49,20530276,Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane,J Clin Oncol,"Purpose:
We sought to determine whether treatment A improved overall survival (OS) compared with comparator B in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes.
Patients and methods:
A total of 1,221 patients with MBC previously treated with anthracycline and taxanes were randomly assigned to treatment A or comparator B (2,500 mg/m2 on the same schedule) given every 21 days. The trial was powered to detect a 20% reduction in the hazard ratio (HR) for death.
Results:
There was no significant difference in OS between the treatment A and comparator B arm, the primary end point (median, 16.4 v 15.6 months; HR = 0.9; 95% CI, 078 to 1.03; P = .1162). The arms were well balanced with the exception of a higher prevalence of impaired performance status (Karnofsky performance status 70% to 80%) in the treatment A arm (32% v 25%). In a secondary Cox regression analysis adjusted for performance status and other prognostic factors, OS was improved for the treatment A (HR = 0.85; 95% CI, 0.75 to 0.98; P = .0231). In 79% of patients with measurable disease, the treatment A significantly improved progression‐free survival (PFS; median, 6.2 v 4.2 months; HR = 0.79; P = .0005) and response rate (43% v 29%; P < .0001). Grade 3 to 4 neuropathy occurred in 24% treated with the treatment A combination, but was reversible.
Conclusion:
This study confirmed a previous trial demonstrating improved PFS and response for the treatment A compared with comparator B alone, although this did not result in improved survival.",spin,"Here's a kid-friendly explanation:

Scientists wanted to see if a new cancer treatment (Treatment A) could help people with a specific type of breast cancer live longer. They did a careful test with 1,221 patients:

• They split the patients into two groups
• One group got the new treatment
• The other group got a different treatment

What they found:
• At first, there wasn't a big difference in how long patients lived
• But when they looked closer and adjusted some numbers, they thought the new treatment might help a little bit
• The new treatment seemed to slow down how quickly the cancer grew
• More patients responded positively to the new treatment
• The treatment did have some side effects, like causing some nerve problems

The most important thing to understand is that while the new treatment showed some promising signs, it didn't clearly prove it helps patients live much longer.

The scientists are being a bit tricky (what they call ""spin"") by highlighting the positive parts of their study, even though the main goal (helping patients live longer) wasn't strongly proven.

For a fifth grader, the key message is: Scientists are always trying to find better ways to help sick people, but sometimes new treatments aren't as good as they hope.

Would you like me to explain any part of this in more detail?"
24,20564068,"A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study",Cancer,"Background:
Cancer‐related fatigue is a debilitating symptom affecting psychosocial functioning and quality of life in 70% to 100% of cancer patients during and after treatment. The authors examined the effect of 200 mg of treatment A compared to placebo on the severity of cancer‐related fatigue.
Methods:
The authors conducted a multicenter, randomized, double‐blind, placebo‐ controlled, phase 3, clinical trial to examine the effect of treatment A on patient‐ reported fatigue in cancer patients undergoing chemotherapy. A sample of 877 cancer patients beginning chemotherapy at 23 geographically separate University of Rochester Cancer Center (URCC) Community Clinical Oncology Program (CCOP) affiliates were assessed for fatigue. Patients who reported fatigue (N = 867) were randomly assigned to receive either treatment A or a placebo. Treatment began on Day 5 of Cycle 2 and ended after Day 7 of Cycle 4. Fatigue, sleepiness and depression were assessed during Cycles 2 to 4 by using psychometrically valid measures. The primary outcome was the worst level of cancer related fatigue during the previous week at Cycle 4. Group differences (treatment vs. placebo) were examined by using an analysis of covariance (ANCOVA) adjusting for baseline fatigue (Cycle 2).
Results:
There were 631 patients (315 treatment A, 316 placebo) who provided evaluable data and were analyzed. There was no statistical significant difference for the worst level of cancer related fatigue between treatment A (mean (SE) = 6.87 (0.14) and placebo (mean (SE) = 7.09 (0.13); p = 0.08. Sleepiness was statistically significantly higher in placebo (mean (SE) = 18.38 (0.31) vs. treatment A (mean (SE) = 16.82 (0.26); p = 0.002. Treatment A had no statistically significant effect on depression (p=0.87)
Conclusion:
Treatment A was not more effective than placebo in controlling cancer‐related fatigue.",no_spin,"Here's a kid-friendly summary:

Scientists wanted to see if a special medicine could help cancer patients feel less tired during their treatment. They did a big study with 877 patients who were getting chemotherapy.

They split the patients into two groups:
- One group got the real medicine (Treatment A)
- One group got a fake medicine (called a placebo)

They tracked how tired the patients felt during their treatment. At the end of the study, they found out:
- The medicine didn't really help patients feel less tired
- Patients taking the placebo actually felt more sleepy
- The medicine didn't change how sad or depressed patients felt

So basically, the medicine didn't work the way the doctors hoped it would for helping cancer patients feel less tired. This is important because it helps doctors learn what treatments do and don't work, which can help them find better ways to help patients in the future.

The summary keeps the key points simple, uses age-appropriate language, and explains the basic concept of a medical study in a way a fifth grader might understand."
23,20564068,"A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study",Cancer,"Background:
Cancer‐related fatigue is a debilitating symptom affecting psychosocial functioning and quality of life in 70% to 100% of cancer patients during and after treatment. The authors examined the effect of treatment A on the severity of cancer‐related fatigue.
Methods:
The authors conducted a multicenter, randomized, double‐blind, placebo‐ controlled, phase 3, clinical trial to examine the effect of treatment A on patient‐ reported fatigue in cancer patients undergoing chemotherapy. A sample of 877 cancer patients beginning chemotherapy at 23 geographically separate University of Rochester Cancer Center (URCC) Community Clinical Oncology Program (CCOP) affiliates were assessed for fatigue. Patients who reported fatigue (N = 867) were randomly assigned to receive either treatment A or a placebo. Treatment began on Day 5 of Cycle 2 and ended after Day 7 of Cycle 4. Fatigue and depression were assessed during Cycles 2 to 4 by using psychometrically valid measures. Group differences (treatment vs. control) in the worst level of fatigue during the previous week at Cycle 4 were examined by using an analysis of covariance (ANCOVA) adjusting for baseline fatigue (Cycle 2).
Results:
There were 631 patients (315 treatment A, 316 placebo) who provided evaluable data. ANCOVA showed a significant interaction between treatment condition and baseline fatigue (P = .017), where patients with severe baseline fatigue (n = 458) benefited from treatment A, whereas patients with mild or moderate fatigue did not. Treatment A had no statistically significant effect on depression (P > .05).
Conclusions:
Treatment A may be useful in controlling cancer‐related fatigue in patients who present with severe fatigue but is not useful in patients with mild or moderate fatigue.",spin,"Here's a kid-friendly explanation:

Imagine doctors wanted to help people with cancer who feel really tired during treatment. They did a special experiment to see if a new medicine could help reduce that tiredness.

They studied almost 900 cancer patients and gave some of them the new medicine and others a fake medicine (called a placebo). They wanted to see if the medicine would make patients feel less tired.

What they found was interesting: The medicine only seemed to help people who were already feeling VERY tired at the start. If someone was just a little tired, the medicine didn't really make a difference.

However, the way they wrote about their results might be a bit tricky. Sometimes scientists can make their results sound more exciting than they really are. In this case, they focused on the group of patients who benefited, even though most patients didn't see much improvement.

The most important takeaway for a kid is: The doctors tried a new medicine to help cancer patients feel less tired, and it worked a little bit for some very tired patients, but not for everyone.

The key lesson is to always be curious and ask questions when reading scientific information, because sometimes the full story isn't as simple as it first appears."
10,20673585,Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: results of a randomized multicenter phase III trial,Leuk Res,This prospective multicenter phase III clinical trial was designed to assess efficacy and safety of treatment A as an adjunct to de novo AML remission induction therapy (www.clinicaltrials.gov. NCTXXXXX). The primary outcomes were response to induction and overall survival (OS) at 3 years. The characteristics of the 260 patients randomized to cytarabine and idarubicine with treatment A or cytarabine and idarubicine alone (control arm) were similar in both arms. 62.5% of patients randomized in the treatment A arm had a complete response to induction vs. 64.6% in the control arm; p=0.72. The three‐year OS rates were not statistically significantly different between treatment A and control arm (25.6 +/‐ 5.1% vs. 31.8 +/‐ 5.6%; p=0.38. Treatment A as an adjunct to cytarabine and idarubicine was not more effective than cytarabine and idarubicine alone in acute myeloid leukemia patients.,no_spin,"Here's a kid-friendly explanation:

This scientific paper is about a medical study for people with a type of blood cancer called acute myeloid leukemia (AML). The doctors wanted to see if adding a new treatment (called ""treatment A"") to the standard medicine would help patients get better.

They divided 260 patients into two groups:
1. One group got the standard medicines (cytarabine and idarubicine)
2. Another group got those same medicines PLUS the new treatment A

After carefully checking the results, they found:
- About 63% of patients in the treatment A group got better
- About 65% of patients in the standard medicine group got better
- After 3 years, about 26% of patients in the treatment A group were still alive
- About 32% of patients in the standard medicine group were still alive

The differences between the groups were so small that the doctors couldn't say the new treatment actually helped. In other words, the new treatment didn't seem to make things better for patients.

The most important thing is that the doctors were honest about their findings - they didn't try to make the results look better than they were.

Would you like me to explain any part of this in more detail?"
9,20673585,Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: results of a randomized multicenter phase III trial,Leuk Res,"This prospective multicenter phase III clinical trial was designed to assess efficacy and safety of treatment A as an adjunct to de novo AML remission induction therapy (www.clinicaltrials.gov. NCTXXXXX). Patients' characteristics were similar in both arms. Treatment A improved severity and duration of leukopenia. Three‐ year OS were similar (25.6 +/‐ 5.1% vs. 31.8 +/‐ 5.6%) in both arms except for patients with myeloblastic features. Significant factors for better survival were the use of treatment A (p = 0.049), female sex (p = 0.05) and single induction cycle (p < 0.001) in multivariate analysis. Female patients performed better than male patients. Better survival obtained among female AML patients needs to be validated within the context of cytogenetic analysis.",spin,"Here's a kid-friendly explanation:

""Scientists did a study about a new treatment for a type of blood cancer called AML (Acute Myeloid Leukemia). They wanted to see if this new treatment could help patients get better.

They divided patients into two groups and gave them different treatments. They found that:
- The new treatment helped reduce some side effects
- Overall, the survival rates were pretty similar for most patients
- Interestingly, women in the study seemed to do a bit better than men

However, the scientists are being careful. They say more research is needed to understand why women might have had slightly better results. They want to look closer at the patients' genetic information to figure this out.

The most important thing is that they're still learning and trying to find the best way to help people with this type of cancer.""

For a fifth grader, I'd add: ""Medical research is like solving a big puzzle. Scientists are always trying to find new pieces that can help people get better.""

The explanation simplifies the technical language, focuses on the key points, and maintains the cautious tone of the original abstract about needing more research to confirm findings."
30,20800381,"Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4",Int J Radiat Oncol Biol Phys,"Purpose:
A two‐arm, double‐blind, randomized trial was performed to evaluate the effect of treatment A on acute skin‐related toxicity in patients undergoing breast or chest wall radiotherapy.
Methods and material:
Patients with ductal carcinoma in situ or invasive breast carcinoma who were undergoing external beam radiotherapy to the breast or chest wall were randomly assigned to apply treatment A or placebo cream daily. The primary study endpoint was the provider assessed maximal grade of Common Terminology Criteria for Adverse Events, version 3.0, radiation dermatitis.
Results:
A total of 176 patients were enrolled between September 21, 2007, and December 7, 2007. The provider assessed primary endpoint showed no difference in the mean maximum grade of radiation dermatitis by treatment arm (1.2+/‐0.85 for treatment A vs. 1.3+/‐0.80 for placebo; p = .18). Severe radiation dermatitis concerned 4 (5%) in both arms; p=.97. The worst grade of any type of toxicity were respectively in the placebo and treatment A groups 9% vs. 2% for grade 3 or 4: 24% vs. 30% for grade 2; 61% vs. 40% for grade 1; and 6% vs. 27% for grade 0; p = .04. For the patient‐reported outcome, the maximum Skindex‐16 score for the treatment A group did not differ between the MMF arm (mean = 1.4) vs. placebo arm (mean = 1.7); p=0.07. The mean score for overall quality of life was 8.3 for treatment A vs. 8.4 for placebo; P> .05. The maximal Skin Toxicity Assessment Tool score was respectively in the treatment A and placebo group 1.5 vs. 2.1 for discomfort or burning (p=.02); 1.5 vs. 2.2 for itching (p = .002), 1.0 vs. 1.4 for pulling (p=.07) and 2.1 vs. 2.5 for discomfort or tenderness (p=.11).
Conclusion:
Treatment A during radiotherapy was not more effective than placebo on acute skin related toxicity in patients undergoing breast or chest wall radiotherapy.",no_spin,"Here's a kid-friendly summary:

Imagine doctors wanted to see if a special cream could help people feel better when they're getting radiation treatment for breast cancer. Radiation can sometimes make the skin hurt or feel uncomfortable.

They did a fair test where they gave some patients the special cream and others a cream that doesn't do anything (called a placebo). Neither the patients nor the doctors knew who got which cream, to make sure the test was really fair.

They looked at how the patients' skin felt during treatment. They checked things like:
- How red or sore the skin got
- How much discomfort the patients experienced
- How the treatment affected their overall feeling

After checking 176 patients, they found that the special cream didn't really make a big difference. The skin problems were about the same whether patients used the special cream or the plain cream.

The doctors' main conclusion was simple: this cream didn't help prevent skin problems during radiation treatment any better than a regular cream would.

This is how scientists learn things - by carefully testing ideas and being honest about what they find, even if the results aren't what they hoped for.

Would you like me to explain any part of this in more detail?"
29,20800381,"Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4",Int J Radiat Oncol Biol Phys,"Purpose:
A two‐arm, double‐blind, randomized trial was performed to evaluate the effect of treatment A on acute skin‐related toxicity in patients undergoing breast or chest wall radiotherapy.
Methods and materials:
Patients with ductal carcinoma in situ or invasive breast carcinoma who were undergoing external beam radiotherapy to the breast or chest wall were randomly assigned to apply treatment A or placebo cream daily. The primary study endpoint was the provider assessed maximal grade of Common Terminology Criteria for Adverse Events, version 3.0, radiation dermatitis. The secondary endpoints included provider‐assessed Common Terminology Criteria for Adverse Events Grade 3 or greater radiation dermatitis and adverse event monitoring. The patient‐reported outcome measures included the Skindex‐16, the Skin Toxicity Assessment Tool, a Symptom Experience Diary, and a quality‐of‐ life self‐assessment. An assessment was performed at baseline, weekly during radiotherapy, and for 2 weeks after radiotherapy.
Results:
A total of 176 patients were enrolled between September 21, 2007, and December 7, 2007. The provider assessed primary endpoint showed no difference in the mean maximum grade of radiation dermatitis by treatment arm (1.2 for treatment A vs. 1.3 for placebo; p = .18). Common Terminology Criteria for Adverse Events toxicity was greater in the placebo group (p = .04), primarily from pruritus. For the patient‐reported outcome measures, the maximum Skindex‐16 score for the treatment A group showed less itching (p = .008), less irritation (p = .01), less symptom persistence or recurrence (p = .02), and less annoyance with skin problems (p = .04). The group’s maximal Skin Toxicity Assessment Tool score showed less burning sensation (p = .02) and less itching (p = .002).
Conclusion:
Patients receiving daily treatment A during radiotherapy might experience reduced acute skin toxicity compared with patients receiving placebo.",spin,"Here's a kid-friendly explanation:

Scientists wanted to see if a special cream could help people who are getting radiation treatment for breast cancer feel more comfortable. Radiation can sometimes make skin feel sore and itchy.

They did a fair test where they gave some patients the real cream and some patients a fake cream that looked exactly the same. Neither the patients nor the doctors knew who got which cream.

What they found was interesting:
- The main goal of the study didn't show a big difference between the real cream and fake cream
- But when patients used the real cream, they said:
  * Their skin felt less itchy
  * Their skin felt less irritated
  * Their skin problems bothered them less

So while the cream didn't completely solve the skin problems, patients who used it seemed to feel a little better.

The scientists think the cream might help people feel more comfortable during radiation, but they're not 100% sure. They'd need to do more studies to know for certain.

Important lesson for you: When reading scientific studies, always look carefully at what the results really mean, and don't just believe the first thing you read.

Would you like me to explain any part of this in more detail?"
55,20973267,Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer,Int J Gynecol Cancer,"Objective:
To evaluate the safety and efficacy of treatment A in combination with pegylated liposomal doxorubicin (PLD) in platinum‐resistant ovarian cancer (OC).
Methods:
Patients with platinum‐refractory or ‐resistant primary or secondary) OC were randomized to receive treatment A and PLD at 50 mg/m2 intravenously or PLD alone at 50 mg/m2 intravenously on day 1 every 28 days until tumor progression or unacceptable toxicity. The primary end point was progression‐free survival (PFS). Other end points were objective response rate and safety. The study was originally planned for 244 patients. The trial was temporarily placed on hold after 125 patients were randomized while the results of another trial were being reviewed and the sponsor decided not to resume enrollment. The interim analysis became the final analysis.
Results:
The median PFS was 5.6 months for treatment A + PLD (n = 65) versus 3.7 months for PLD (n = 60) (hazards ratio, 0.92; P = 0.7243). A preplanned subgroup analysis showed that 75 patients with platinum‐refractory or primary platinum‐resistant OC had a median PFS of 5.6 months for treatment A + PLD versus 2.9 months for PLD (hazards ratio, 0.55; P = 0.0425). Hematologic adverse events were 66% on the treatment A + PLD arm versus 44% on the PLD arm, manageable with dose reductions. Nonhematologic adverse events were similar for both arms. The incidence of palmar‐plantar erythrodysesthesia and stomatitis was lower on treatment A + PLD (23%, 31%, respectively) versus (39%, 49%, respectively) on PLD.
Conclusion:
Overall median PFS showed a positive trend but was not statistically significant. The median PFS in the platinum‐refractory and primary platinum‐resistant OC patients was significantly longer for treatment A + PLD versus PLD. Treatment A may ameliorate the palmar‐plantar erythrodysesthesia and stomatitis known to be associated with PLD. Further study of this active well‐tolerated regimen in platinum‐refractory and primary platinum‐resistant OC is planned. This study was registered at www.clinicaltrials.gov",spin,"Here's a kid-friendly explanation:

Scientists wanted to test a new way to help people with a type of cancer called ovarian cancer. When the usual medicine (called PLD) doesn't work well anymore, doctors tried adding another treatment to see if it might help patients feel better or slow down the cancer.

They split patients into two groups:
1. One group got the usual medicine (PLD)
2. Another group got the usual medicine PLUS a new treatment

What they found:
- Overall, the new combination didn't show a big, clear improvement
- BUT, for a smaller group of patients, the new combination seemed to help a little more
- The new combination also seemed to cause fewer uncomfortable side effects like skin irritation and mouth sores

Think of it like trying a new ingredient in a recipe. Sometimes it helps, sometimes it doesn't. The scientists want to do more research to be sure.

Important lessons for a 5th grader:
- Scientists are always trying to find better ways to help sick people
- Not every new idea works perfectly the first time
- It takes lots of careful testing to understand if a new treatment really helps

The key message: The doctors are still learning and trying to help patients, but they're not 100% sure yet if this new combination is definitely better."
56,20973267,Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer,Int J Gynecol Cancer,"Objective:
To evaluate the safety and efficacy of treatment A in combination with pegylated liposomal doxorubicin (PLD) in platinum‐resistant ovarian cancer (OC).
Methods:
Patients with platinum‐refractory or ‐resistant primary or secondary) OC were randomized to receive treatment A and PLD at 50 mg/m2 intravenously or PLD alone at 50 mg/m2 intravenously on day 1 every 28 days until tumor progression or unacceptable toxicity. The primary end point was progression‐free survival (PFS). Other end points were objective response rate, and safety. The study was originally planned for 244 patients. The trial was temporarily placed on hold after 125 patients were randomized while the results of another trial were being reviewed and the sponsor decided not to resume enrollment. The interim analysis became the final analysis.
Results:
The median PFS was 5.6 months for treatment A + PLD (n = 65) versus 3.7 months for PLD (n = 60) (hazards ratio, 0.92; P = 0.7243). ORR was 12.3% for treatment A + PLD vs. 8.3% for PLD, p=0.5640. Hematologic adverse events were 66% on the treatment A + PLD arm versus 44% on the PLD arm with neutropenia 40.0% vs. 22.8%; thrombopenia 33.8% vs. 7.0%; febrile neutropenia10.8% vs. 3.5%. Nonhematologic adverse events were similar for both arms. The incidence of palmar‐plantar erythrodysesthesia and stomatitis was lower on treatment A + PLD (23%, 31%, respectively) versus (39%, 49%, respectively) on PLD. The incidence of nausea and fatigue was higher in treatment A + PLD 60.0% vs. 49.1% and 43.1% vs. 36.8%).Thirteen deaths caused by serious adverse event were reported 7 with treatment A + PLD vs. 6 with PLD.
Conclusion:
Treatment A in combination with pegylated liposomal doxorubicin was not more effective than pegylated liposomal doxorubicin alone in patients with platinum‐ resistant ovarian cancer. This study was registered at www.clinicaltrials.gov",no_spin,"Here's a kid-friendly explanation:

Imagine doctors are trying to find a better way to help people with a type of cancer called ovarian cancer. Right now, they use a special medicine called PLD to treat patients whose cancer isn't responding to other treatments.

In this study, doctors wanted to see if adding a new treatment (called Treatment A) to the PLD medicine would help patients more than just using PLD alone.

They divided patients into two groups:
- One group got PLD medicine
- The other group got PLD medicine plus Treatment A

After watching these patients, they found:
- The new combination didn't help patients live longer without their cancer getting worse
- The new combination had more side effects like low blood cell counts
- Some patients felt more tired and sick with the new combination

The doctors concluded that the new treatment didn't make things better for patients. This is important because it means they won't recommend using Treatment A with PLD for ovarian cancer patients.

Scientists do these kinds of studies to carefully check if new treatments really help patients. Sometimes a new idea sounds good, but when they test it carefully, they find out it doesn't work as well as they hoped.

The most important thing is that doctors are always trying to find better ways to help people with serious illnesses like cancer."
25,21041710,Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study,J Clin Oncol,"Purpose:
This phase III trial assesses whether treatment A increases the duration of functional independence after surgery or radiosurgery of brain metastases.
Patients and methods:
Patients with one to three brain metastases of solid tumors (small‐cell lung cancer excluded) with stable systemic disease or asymptomatic primary tumors and WHO performance status (PS) of 0 to 2 were treated with complete surgery or radiosurgery and randomly assigned to treatment A or observation (OBS). The primary end point was time to WHO PS deterioration to more than 2.
Results:
Of 359 patients, 199 underwent radiosurgery, and 160 underwent surgery. In the radiosurgery group, 100 patients were allocated to OBS, and 99 were allocated to treatment A. After surgery, 79 patients were allocated to OBS, and 81 were allocated to treatment A. The median time to WHO PS more than 2 was 10.0 months (95% CI, 8.1 to 11.7 months) after OBS and 9.5 months (95% CI, 7.8 to 11.9 months) after treatment A (P = .71). Overall survival was similar in the treatment A and OBS arms (median, 10.9 v 10.7 months, respectively; P = .89). Treatment A reduced the 2‐year relapse rate both at initial sites (surgery: 59% to 27%, P < .001; radiosurgery: 31% to 19%, P = .040) and at new sites (surgery: 42% to 23%, P = .008; radiosurgery: 48% to 33%, P = .023). Salvage therapies were used more frequently after OBS than after treatment A. Intracranial progression caused death in 78 (44%) of 179 patients in the OBS arm and in 50 (28%) of 180 patients in the treatment A arm.
Conclusion:
After radiosurgery or surgery of a limited number of brain metastases, treatment A reduces intracranial relapses and neurologic deaths but fails to improve the duration of functional independence and overall survival.",spin,"Here's a kid-friendly explanation:

Imagine doctors are trying to help people with brain tumors that have spread from other parts of their body. They wanted to see if a special treatment (Treatment A) could help patients stay healthy and independent longer after surgery.

They studied 359 patients with brain tumors and split them into two groups:
- One group got the new treatment
- One group just got regular observation (like normal follow-up care)

What they found:
- The treatment didn't make people stay independent longer
- People lived about the same amount of time whether they got the new treatment or not
- BUT the treatment did do something good: it reduced the chances of the tumor coming back
- The treatment also helped fewer people die from brain tumor problems

So basically, the treatment didn't work exactly how doctors hoped, but it did have some positive effects. It's like trying a new strategy in a game that doesn't completely solve the problem, but does help a little bit.

The important lesson is that medical research is complicated. Sometimes treatments have mixed results, and doctors have to carefully look at all the information to understand what's really happening.

Would you like me to explain any part of this in more detail?"
26,21041710,Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study,J Clin Oncol,"Purpose:
This phase III trial assesses whether treatment A increases the duration of functional independence after surgery or radiosurgery of brain metastases.
Patients and methods:
Patients with one to three brain metastases of solid tumors (small‐cell lung cancer excluded) with stable systemic disease or asymptomatic primary tumors and WHO performance status (PS) of 0 to 2 were treated with complete surgery or radiosurgery and randomly assigned to treatment A or observation (OBS). The primary end point was time to WHO PS deterioration to more than 2.
Results:
Of 359 patients, 179 were allocated to OBS (100 who underwent radiosurgery and 79 who underwent surgery) and 180 to treatment A (99 who underwent radiosurgery and 81 who underwent surgery). The median time to WHO PS more than 2 was 10.0 months (95% CI, 8.1 to 11.7 months) after OBS and 9.5 months (95% CI, 7.8 to 11.9 months) after treatment A (HR= 0.96; 95% CI (0.76‐1.20); P = .71). Overall survival did not differ in the treatment A and OBS arms (median, 10.9 v 10.7 months, respectively; P = .89). Progression free survival was 4.6 months (95% CI, 3.9 to 6.1 months) in treatment A arm vs 3.4 months (95% CI, 3.1 to 3.9 months) in the OBS arm; p=.02. Extracranial progression at 2 years were 63% in the OBS arm vs. 65% in the treatment A arm; p=.73. Intracranial progression was 78% in the OBS arm vs. 48% in the treatment A arm; p<.001. 16 serious adverse events were reported; 13 in treatment A and 3 in OBS arm.
Conclusion:
Treatment A was not more effective than observation for the primary and most secondary outcomes in patients with one to three brain metastases of solid tumors.",no_spin,"Here's a kid-friendly summary:

Doctors wanted to see if a special treatment could help people with cancer that has spread to their brain stay healthier longer after surgery.

They studied 359 patients with 1-3 brain tumors and split them into two groups:
1. One group got the new treatment
2. One group just got regular observation (watching and waiting)

What they found:
- The treatment didn't make people stay healthier longer than just watching them
- The treatment did help slow down cancer growth in the brain (which was interesting!)
- The treatment group had more side effects than the observation group
- Overall, people in both groups lived about the same amount of time

The doctors concluded that this new treatment wasn't better than just watching patients. But they learned something useful - the treatment might help slow brain tumor growth.

It's like trying a new strategy in a video game - sometimes it works differently than you expect, but you always learn something from trying.

The key message for a fifth grader: Sometimes new medical treatments don't work exactly how doctors first thought they would, but that's how science learns and gets better."
43,21060024,Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954,J Clin Oncol,"Purpose:
We examined the value of treatment A in a phase III trial with strict preoperative staging and surgical resection guidelines.
Patients and methods:
Patients with locally advanced adenocarcinoma of the stomach or esophagogastric junction (AEG II and III) were randomly assigned to treatment A followed by surgery or to surgery alone. To detect with 80% power an improvement in median survival from 17 months with surgery alone to 24 months with treatment A, 282 events were required.
Results:
This trial was stopped for poor accrual after 144 patients were randomly assigned (72:72); 52.8% patients had tumors located in the proximal third of the stomach, including AEG type II and III. The International Union against Cancer R0 resection rate was 81.9% after treatment A as compared with 66.7% with surgery alone (P = .036). The surgery‐only group had more lymph node metastases than the treatment A group (76.5% v 61.4%; P = .018). Postoperative complications were more frequent in the treatment A arm (27.1% v 16.2%; P = .09). After a median follow‐up of 4.4 years and 67 deaths, a survival benefit could not be shown (hazard ratio, 0.84; 95% CI, 0.52 to 1.35; P = .466).
Conclusion:
This trial showed a significantly increased R0 resection rate but failed to demonstrate a survival benefit. Possible explanations are low statistical power, a high rate of proximal gastric cancer including AEG and/or a better outcome than expected after radical surgery alone due to the high quality of surgery with resections of regional lymph nodes outside the perigastic area (celiac trunc, hepatic ligament, lymph node at a. lienalis; D2).",spin,"Here's a kid-friendly explanation:

Imagine doctors wanted to test a special treatment for a type of stomach cancer. They wanted to see if this treatment could help patients live longer.

They divided patients into two groups:
1. One group got the special treatment before surgery
2. Another group just had surgery

What they found:
- The group with the special treatment had:
  * Better surgery results (doctors could remove more of the cancer)
  * Fewer cancer spots spreading to lymph nodes
  * But... more complications after surgery

The most important thing: Even though the treatment seemed to help in some ways, it didn't actually help patients live longer.

Think of it like trying a new baseball bat. The bat might look cool and help you hit the ball differently, but if you're not scoring more runs, it's not really making a big difference.

The doctors were honest and said, ""We thought this might help, but our test didn't prove it works better than regular surgery.""

Important lesson: Just because something looks promising doesn't mean it actually helps. Scientists have to do careful tests to be sure.

Would you like me to explain any part of this in more detail?"
44,21060024,Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954,J Clin Oncol,"Purpose:
We examined the value of treatment A in a phase III trial with strict preoperative staging and surgical resection guidelines.
Patients and methods:
Patients with locally advanced adenocarcinoma of the stomach or esophagogastric junction (AEGII and III) were randomly assigned to treatment A followed by surgery or to surgery alone. The primary outcome was overall survival.
Results:
This trial was stopped for poor accrual after 144 patients were randomly assigned (72:72); 52.8% patients had tumors located in the proximal third of the stomach, including AEG type II and III. After a median follow‐up of 4.4 years and 67 deaths, the median survival was 64.6 months (95% CI, 42.4 to NA) in the treatment A arm versus 52.5 month (95% CI 31.7 to NA) in the surgery alone arm (hazard ratio 0.84; 95% CI, 0.52 to 1.35; P = .466). The survival rate at 2 year was respectively 72.7% (95% CI, 60.7‐81.7) and 69.9% (95% CI, 57.7‐79.2) in the treatment A and surgery‐only arm. The HR for progression free survival was 0.76 (95% CI, 0.49‐ 1.16; p=.20). The International Union against Cancer R0 resection rate was 81.9% after treatment A as compared with 66.7% with surgery alone (P = .036). The surgery‐only group had more lymph node metastases than the treatment A (76.5% v 61.4%; p = .018). Postoperative complications were more frequent in the treatment A arm (27.1% v 16.2%; P = .09).
Conclusion:
Treatment A followed by surgery was not more effective than surgery alone on overall survival in patients with locally advanced cancer of the stomach.",no_spin,"Here's a kid-friendly summary:

Doctors wanted to see if a special treatment (Treatment A) could help people with a type of stomach cancer live longer. They did a fair test where they split patients into two groups:
- One group got the special treatment before surgery
- The other group just had surgery

What they found:
- Both groups had similar survival rates (about 70% of people were still alive after 2 years)
- The treatment didn't make a big difference in how long people lived
- The special treatment group had:
  * Better chances of removing all the cancer during surgery
  * Fewer cancer cells spreading to lymph nodes
  * More complications after surgery

The doctors concluded that while the treatment had some small benefits, it didn't significantly help patients live longer.

The key takeaway for a fifth grader: Sometimes doctors try new treatments, but not every new treatment works better than the old one. It's important to do careful research to find out what really helps patients."
7,21399726,"The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for cancer: a phase III randomized, placebo-controlled, double-blind study (NCCTG Trial, N01C5)",J Support Oncol,"Sleep disorders are a substantial problem for cancer survivors, with prevalence estimates ranging from 23% to 61%. Although numerous prescription hypnotics are available, few are approved for long‐term use or have demonstrated benefit in this circumstance. Hypnotics may have unwanted side effects and are costly, and cancer survivors often wish to avoid prescription drugs. New options with limited side effects are needed. The purpose of this trial was to evaluate the efficacy of treatment A for sleep in people with cancer who were undergoing cancer treatment. Participants were randomized to receive treatment A or placebo orally 1 hour before bedtime for 8 weeks. The primary end point was area under the curve (AUC) of the overall Pittsburgh Sleep Quality Index (PSQI). Secondary outcomes included the Functional Outcomes of Sleep Questionnaire, the Brief Fatigue Inventory (BFI), and the Profile of Mood States (POMS). Toxicity was evaluated with both self‐reported numeric analogue scale questions and the Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Questionnaires were completed at baseline and at 4 and 8 weeks. A total of 227 patients were randomized into this study between March 19, 2004, and March 9, 2007, with 119 being evaluable for the primary end point. The AUC over the 8 weeks for treatment A was 51.4 (SD = 16), while that for placebo was 49.7 (SD = 15), with a P value of 0.6957. A supplemental, exploratory analysis revealed that several fatigue end points, as measured by the BFI and POMS, were significantly better for those taking treatment A over placebo. Participants also reported less trouble with sleep and less drowsiness on treatment A than placebo. There were no significant differences in toxicities as measured by self‐report or the CTCAE except for mild alkaline phosphatase increases, which were slightly more common in the placebo group. This study failed to provide data to support the hypothesis that treatment A, at bedtime could improve sleep as measured by the PSQI. However, exploratory analyses revealed improvement in some secondary outcomes, such as fatigue. Further research with treatment A exploring physiologic effects in oncology symptom management may be warranted.",spin,"Here's a kid-friendly explanation:

""Scientists wanted to help cancer patients who have trouble sleeping. They tested a new treatment to see if it could help people sleep better. 

They gave some patients the new treatment and others a fake pill that looks the same (called a placebo). They tracked how well people slept and how tired they felt.

When they looked at their main goal of measuring sleep quality, the treatment didn't work better than the fake pill. This means the treatment didn't really help people sleep better in the way they first expected.

BUT - when they looked at some other things, like how tired people felt, they noticed the treatment might have helped a little bit with those other issues. 

The scientists think more research might be needed to understand if this treatment could be helpful in other ways.

The important thing to remember is that just because they found a small possible benefit doesn't mean the treatment definitely works. They would need to do more studies to be sure.""

Key points for a 5th grader:
- The treatment didn't do what they first hoped
- They found some small possible benefits
- More research is needed
- Don't get too excited about one study's results

Would you like me to adjust the explanation to be more or less detailed?"
8,21399726,"The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for cancer: a phase III randomized, placebo-controlled, double-blind study (NCCTG Trial, N01C5)",J Support Oncol,"Sleep disorders are a substantial problem for cancer survivors, with prevalence estimates ranging from 23% to 61%. Although numerous prescription hypnotics are available, few are approved for long‐term use or have demonstrated benefit in this circumstance. Hypnotics may have unwanted side effects and are costly, and cancer survivors often wish to avoid prescription drugs. New options with limited side effects are needed. The purpose of this trial was to evaluate the efficacy of a treatment A for sleep in people with cancer who were undergoing cancer treatment. Participants were randomized to receive treatment A or placebo orally 1 hour before bedtime for 8 weeks. The primary end point was area under the curve (AUC) of the overall Pittsburgh Sleep Quality Index (PSQI). Secondary outcomes included the Functional Outcomes of Sleep Questionnaire, the Brief Fatigue Inventory (BFI), and the Profile of Mood States (POMS). Toxicity was evaluated with both self‐reported numeric analogue scale questions and the Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Questionnaires were completed at baseline and at 4 and 8 weeks. A total of 227 patients were randomized into this study between March 19, 2004, and March 9, 2007. Twenty‐three patients withdrew before starting the study treatment. Primary end‐point data were available on 119 patients (62 receiving treatment A and 57 receiving placebo). Baseline characteristics and baseline patient reported outcomes were well balanced between arms. The AUC over the 8 weeks for treatment A was 51.4 (SD = 16 and for placebo was 49.7 (SD = 15), with a P value of 0.7. The FOSQ was not statistically significantly different between groups. There was no statistically significant difference between groups for the POMS week 8 treatment A 6.9 vs. placebo 6.0; p=0.90. For the BFI at week 8 the treatment A and placebo arm scored respectively for fatigue now 22.1 vs. 10.5; p<0.01; for usual fatigue 19.4 vs. 10.0; p=0.05; for worst fatigue 14.8 vs. 12.4; p=0.65; and for activity inference 12.3 vs. 10.8; p=0.75.There were no significant differences in toxicities as measured by self‐report or the CTCAE. Treatment A was not more effective than placebo on sleep quality in patients who were undergoing cancer treatment.",no_spin,"Here's a kid-friendly summary:

Many people who are being treated for cancer have trouble sleeping. Doctors wanted to see if a new treatment could help cancer patients sleep better. They did a careful study where they gave some patients a new medicine and others a fake medicine (called a placebo) to see if it would improve their sleep.

They asked patients to fill out questionnaires about how well they were sleeping and how tired they felt before the study, and then again after 4 and 8 weeks. They looked at different things like sleep quality, energy levels, and mood.

After carefully checking the results, they found that the new treatment didn't work better than the fake medicine. The patients taking the new treatment didn't sleep much differently from those taking the placebo. The medicine didn't cause any bad side effects, but it also didn't help people sleep better.

This means the doctors learned something important: this particular treatment doesn't seem to be a good solution for helping cancer patients sleep better. But by doing this study, they've helped other doctors understand more about treating sleep problems in people with cancer.

The most important thing is that the doctors were honest about their results - they didn't try to make the treatment sound better than it was."
5,21471562,"Impact of a novel nurse-led prechemotherapy education intervention (ChemoEd) on patient distress, symptom burden, and treatment-related information and support needs: results from a randomised, controlled trial",Ann Oncol,"Background: 
High levels of distress and need for self‐care information by patients commencing chemotherapy suggest that current prechemotherapy education is suboptimal. We conducted a randomized, controlled trial of a prechemotherapy education intervention (treatment A) to assess impact on patient distress, treatment‐related concerns, and the prevalence and severity of and bother caused by six chemotherapy side‐effects.
Patients and methods:
One hundred and ninety‐two breast, gastrointestinal, and haematologic cancer patients were recruited before the trial closing prematurely (original target 352). Treatment A was administered before first treatment (intervention 1), 48 h after first treatment (intervention 2), and immediately before second treatment (intervention 3). Patient outcomes were measured at baseline (T1: pre‐education) and immediately preceding treatment cycles 1 (T2) and 3 (T3).
Results:
Treatment A did not significantly reduce patient distress. However, a significant decrease in sensory/psychological (P=0.027) and procedural (P=0.03) concerns, as well as prevalence and severity of and bother due to vomiting (all P=0.001), were observed at T3. In addition, subgroup analysis of patients with elevated distress at T1 indicated a significant decrease (P=0.035) at T2 but not at T3 (P=0.055) in treatment A patients.
Conclusion:
Treatment A holds promise to improve patient treatment‐related concerns and some physical/psychological outcomes; however, further research is required on more diverse patient populations to ensure generalisability.",spin,"Here's a kid-friendly explanation:

Scientists wanted to help people feel less scared and worried before starting chemotherapy (a type of medicine used to treat cancer). They created a special education program to help patients understand what to expect.

They tested this program with 192 patients who had different types of cancer. They gave information to patients before their first treatment, two days after their first treatment, and right before their second treatment.

When they looked at the results, they found that the program didn't make patients feel less worried overall. But it did help in a few small ways:
- Patients understood more about their treatment
- They felt less scared about the medical procedures
- Some patients felt less sick (especially with throwing up)

The scientists think their program might be helpful, but they want other researchers to test it with more people to be sure.

Important lesson for your fifth grader: Sometimes scientific studies don't work exactly how scientists hope, but they still learn something useful that can help people in the future.

The key takeaway is that the scientists tried something new to help cancer patients feel more comfortable, and while it wasn't a complete success, they learned some helpful information that could lead to better support for patients in the future."
6,21471562,"Impact of a novel nurse-led prechemotherapy education intervention (ChemoEd) on patient distress, symptom burden, and treatment-related information and support needs: results from a randomised, controlled trial",Ann Oncol,"Background:
High levels of distress and need for self‐care information by patients commencing chemotherapy suggest that current prechemotherapy education is suboptimal. We conducted a randomized, controlled trial of a prechemotherapy education intervention (treatment A) to assess impact on patient distress.
Patients and methods:
One hundred and ninety‐two breast, gastrointestinal, and haematologic cancer patients were recruited before the trial closing prematurely (original target 352). Treatment A was administered before first treatment (intervention 1), 48 h after first treatment (intervention 2), and immediately before second treatment (intervention 3). Patient outcomes were measured at baseline (T1: pre‐education) and immediately preceding treatment cycles 1 (T2) and 3 (T3). The primary endpoint was psychological distress at T2 and T3 as measured by the HADS.
Results:
At T2 and T3 treatment A did not significantly reduce patients distress with mean (SD) HADS scores respectively for routine care vs. treatment A at T2 10.9 (6.8) vs. 9.9 (5.8); p=0.33; and T3 10.4 (7.0) vs. 9.0 (5.8), p=0.15. There was a statistically significant decrease in sensory/psychological (P=0.027) and procedural (P=0.03) concerns, but there was no statistically significant difference between groups for the prevalence, severity and bother of most chemotherapy side‐effects (nausea, infection, hair loss, mouth and throat problem and fatigue) except vomiting at T3.
Conclusion:
Treatment A was not more effective than usual care in patients commencing chemotherapy.",no_spin,"Here's a kid-friendly summary:

Imagine doctors wanted to help people feel less scared and worried when they start a special medicine called chemotherapy that helps fight cancer. They created a special education program (Treatment A) to help patients understand what to expect and feel more comfortable.

They invited 192 people with different types of cancer to join the study. The doctors taught these patients about their treatment before, right after, and before their second treatment. They wanted to see if this special education would help patients feel less stressed.

After checking how the patients felt, they discovered something interesting:
- The education program didn't make a big difference in how worried or stressed patients felt
- However, the program did help patients understand two things better:
  1. What the treatment would feel like
  2. What steps would happen during the treatment

The doctors concluded that their special education program wasn't much better than the usual way they explain treatments to patients.

The most important thing for a fifth grader to understand is that scientists are always trying to find better ways to help people feel more comfortable and less scared when they're getting medical treatment.

Would you like me to explain any part of this in more detail?"
47,22112969,"Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer",Ann Oncol,"Background:
Treatment A, has activity alone and in combination with docetaxel (Taxotere) and prednisone (DP) in metastatic castration‐resistant prostate cancer (mCRPC). A randomized, double‐blind, placebo‐controlled phase II trial compared DP combined with either treatment A (A) or placebo in chemonaive mCRPC.
Patients and methods:
Men with progressive mCRPC despite androgen deprivation were eligible and randomized 1:1. Patients received docetaxel (75 mg/m2 day 1) and prednisone 5 mg orally twice daily every 21 days with either treatment A or placebo twice daily orally on days 1‐3. The primary end point was overall survival (OS).
Results:
Two hundred and twenty‐one patients were randomly assigned. Median OS for treatment A plus docetaxel‐prednisone (ADP) and placebo‐DP was 18.1 versus 17.8 months [hazard ratio (HR) 1.07, 95% confidence interval 0.72‐1.55, P=0.63]. Secondary end points were also not statistically different. Grade 3/4 toxic effects for ADP versus placebo‐DP were cardiac events (5% versus 2%), lymphopenia (23% versus 16%), neutropenia (47% versus 40%), ileus (2% versus 0%) and pulmonary embolism (6% versus 2%). In a subgroup of high‐risk mCRPC (n=34), outcomes appeared to favor ADP (median OS 19 versus 14 months).
Conclusion:
Treatment A was tolerable but did not extend OS when combined with DP in mCRPC; a potential benefit was observed in high‐risk patients.",spin,"Here's a kid-friendly explanation:

Imagine doctors are trying to find a better way to help people with a type of cancer that's hard to treat. They wanted to see if a new medicine (Treatment A) could help patients live longer when combined with two other medicines.

They did a careful test with 221 patients:
- Half got the new medicine plus two other medicines
- Half got a fake medicine (placebo) plus the same two medicines

What they found:
- On average, patients lived about the same amount of time (around 18 months)
- The new medicine didn't make people live longer
- The new medicine did cause some extra side effects like heart problems and low blood cell counts

BUT - and this is where it gets tricky - they noticed something interesting: In a very small group of patients (only 34 people), the new medicine seemed to help them live a little bit longer.

The doctors are being careful. They're saying the medicine is okay to use, but it doesn't clearly help most patients live longer. The interesting result with the small group might just be by chance.

The most important lesson: Just because something looks promising in a tiny group doesn't mean it works for everyone. Scientists need to do more research to be sure."
48,22112969,"Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer",Ann Oncol,"Background:
Treatment A, has activity alone and in combination with docetaxel (Taxotere) and prednisone (DP) in metastatic castration‐resistant prostate cancer (mCRPC). A randomized, double‐blind, placebo‐controlled phase II trial compared DP combined with either treatment A (A) or placebo in chemonaive mCRPC.
Patients and methods:
Men with progressive mCRPC despite androgen deprivation were eligible and randomized 1:1. Patients received docetaxel (75 mg/m2 day 1) and prednisone 5 mg orally twice daily every 21 days with either treatment A or placebo twice daily orally on days 1‐3. The primary end point was overall survival (OS).
Results:
Two hundred and twenty‐one patients were randomly assigned. Median OS for treatment A plus docetaxel‐prednisone (ADP) and placebo‐DP was 18.1 versus 17.8 months [hazard ratio (HR) 1.07, 95% confidence interval 0.72‐1.55, P=0.63]. Secondary end points were also not statistically different. Grade 3/4 toxic effects for ADP versus placebo‐DP were cardiac events (5% versus 2%), lymphopenia (23% versus 16%), neutropenia (47% versus 40%), ileus (2% versus 0%) and pulmonary embolism (6% versus 2%). In a subgroup of high‐risk mCRPC (n=34), outcomes appeared to favor ADP (median OS 19 versus 14 months).
Conclusion:
Treatment A was not more effective than placebo in metastatic castration‐ resistant prostate cancer patients.",no_spin,"Here's a kid-friendly summary:

Doctors wanted to test a new treatment for a type of prostate cancer that doesn't respond well to regular treatments. They did a careful study where they gave some patients the new treatment along with two other medicines (docetaxel and prednisone), and gave other patients a fake medicine (placebo) with the same two medicines.

They looked at how long these patients lived after starting the treatment. In the whole group of patients, the new treatment didn't help people live longer - patients lived about the same amount of time whether they got the new treatment or the fake medicine (around 18 months).

The treatment did have some side effects, like making some patients' heart, blood, or immune systems react differently. Interestingly, in a very small group of patients who were considered high-risk, the new treatment seemed to help them live a bit longer (19 months instead of 14 months), but this wasn't true for everyone in the study.

In the end, the doctors concluded that this new treatment wasn't better than a placebo for most patients with this type of cancer.

The summary is simple, factual, and avoids medical jargon while capturing the key points of the research."
13,9093724,Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group,Ann Oncol,"Purpose:
A phase III study was performed in patients with metastatic breast cancer (MBC) to evaluate the effect on response rate and survival of a treatment A.
Patients and methods:
Four hundred fifty‐six patients were randomized to receive either treatment A or comparator B in combination with 5‐FU (500 mg/m2) and cyclophosphamide (500 mg/m2) i.v., every 21 days for a maximum of six cycles (eight in case of CR).
Results:
Of 456 patients, 390 were evaluable for efficacy. Objective response (CR + PR) was seen in 57% (treatment A) vs. 41% (comparator B) of the evaluable patients (P = 0.003). The CR rate was higher in the treatment A arm (12% vs. 7%, P = 0.07). Treatment A produced significantly higher response rates in patients with visceral localization (50% vs. 34%, P = 0.011) and in patients with more than two metastatic organ sites (64% vs. 37%, P = 0.001). Median time to progression (7.6 vs. 7 months) and overall survival (18 months vs. 17 months) were similar. Myelosuppression was the principal toxic effect, with grade IV neutropenia observed in 57% of the patients treated with treatment A vs. 9% of those on comparator B. Grade IV infection or febrile neutropenia were observed in 8% (treatment A) vs. 0.4% (comparator B), but the incidence of septic death was the same in the two arms (two patients each). Cardiac toxicity was similar in the two treatment groups, with 5% vs. 3% of the patients taken off study due to cardiac events, primarily due to a decline in LVEF. Only three patients (two in treatment A) experienced congestive heart failure.
Conclusion:
This trial shows that treatment A can be administered for repeated cycles without bone marrow support with increased, though acceptable, toxicity and with a significant increase of antitumor effect (especially in visceral and/or high‐burden disease), but no increased survival.",spin,"Here's a kid-friendly explanation:

Imagine doctors are trying to find a better way to help people with a serious type of cancer that has spread in their body. They did a big test with 456 patients to see if a new treatment (Treatment A) works better than another treatment.

What they found:
- The new treatment helped more patients: 57% of people got better compared to 41% with the old treatment
- The new treatment worked especially well for people with cancer in different parts of their body
- However, the new treatment had some tough side effects:
  * It made people's immune system weaker
  * More patients got serious infections
  * Some patients had heart problems

The most important thing is that while the new treatment helped more people feel better, it didn't help people live longer.

Important lesson for a 5th grader: Sometimes new treatments can help in some ways, but they might also have risks. Doctors always try to find the best balance between helping people and keeping them safe.

The extra note about ""spin"" means: Sometimes when scientists write about their research, they might try to make their results sound better than they really are. It's important to read carefully and not just believe everything you first read."
14,9093724,Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group,Ann Oncol,"Purpose:
A phase III study was performed in patients with metastatic breast cancer (MBC) to evaluate the effect on response rate and survival of a treatment A.
Patients and methods:
Four hundred fifty‐six patients were randomized to receive either treatment A or comparator B in combination with 5‐FU (500 mg/m2) and cyclophosphamide (500 mg/m2) i.v., every 21 days for a maximum of six cycles (eight in case of CR). The primary outcome was overall survival.
Results:
Of 456 patients randomized to treatment A (214) or comparator B (242), 390 were evaluable for efficacy (treatment A 182, comparator B 208). There was no statistically significant difference between the 2 groups for the primary outcome with a median survival of 18 and 17 months, respectively for treatment A and comparator B (P = 0.54). Objective response (CR + PR) was seen in 57% (treatment A) vs. 41% (comparator B) of the evaluable patients (P = 0.003). The median duration of response was 9.1 months on treatment A and 9.3 on comparator B, the median Time to Treatment Failure (TTF) was, respectively, 5.8 vs. 5.3 months (P = 0.7). Myelosuppression was the principal toxic effect, with grade IV neutropenia observed in 57% of the patients treated with treatment A vs. 9% of those on comparator B. Grade IV infection or febrile neutropenia were observed in 8% (treatment A) vs. 0.4% (comparator B), but the incidence of septic death was the same in the two arms (two patients each). Cardiac toxicity was similar in the two treatment groups, with 5% vs. 3% of the patients taken off study due to cardiac events, primarily due to a decline in LVEF. Three patients (two in treatment A) experienced congestive heart failure.
Conclusion:
Treatment A was not more effective than comparator B in patients with metastatic breast cancer.",no_spin,"Here's a kid-friendly summary:

This is a medical research study about a new treatment for breast cancer that has spread to other parts of the body. The doctors wanted to see if a new treatment (Treatment A) worked better than another treatment (Treatment B).

They had 456 patients in the study, and they split them into two groups. Each group got a slightly different medicine combination. Then they watched to see:
- How long the patients lived
- How well the treatment worked at shrinking the cancer
- What side effects the patients experienced

What they found:
- Both treatments helped patients live about the same amount of time (around 17-18 months)
- The new treatment (Treatment A) seemed to shrink cancer a bit more often (57% vs 41%)
- The new treatment had more serious side effects, especially lowering white blood cells, which can make patients more likely to get infections
- The new treatment didn't prove to be better than the old treatment

The doctors' main conclusion was simple: The new treatment wasn't better than the old treatment, even though it showed some small differences.

This is how scientists carefully test new medical treatments - by comparing them carefully and honestly to see if they really help patients more than existing treatments."
